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Summary
This study:
T. Investigates the influence of S. frutescens on the binding properties of cytochrome
P450-dependent enzymes in ovine adrenocortical mitochondria and microsomes,
demonstrating that S. frutescens extracts elicit difference spectra and inhibit the
Type 1difference spectra induced by natural steroids.
IT. Indicates inhibition by S. frutescens extracts of the catalytic activity of
cytochrome P450-dependent-17a-hydroylase and cytochrome P450-dependent-
steroid-21-hydroxylase enzymes in ovine adrenocortical microsomes.
III. Describes an assay determining the inhibitory effects of S. frutescens, in COS L
cells, on individual cytochrome P450-dependent enzymes - ovine, baboon and
human cytochrome P450-dependent- L7a-hydroylase, and bovine cytochrome
P450-dependent-21-hydroxylase enzymes.
lY. Demonstrates that the inhibition of elevated plasma glucocorticoid levels in rats
exposed to chronic immobilization stress could possibly be attributed to the
influence of hydrophilic and hydrophobic compounds in S. frutescens on
cytochromes P450-depndent enzymes.
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Opsomming
Hierdie studie:
1. Ondersoek die invloed van S. frutescens op die bindingseienskappe van
sitochroom P450-afhanklike ensieme in skaapbynier mitokondriale en -
mikrosomale preparate en toon aan dat komponente in S. frutescens ekstrakte
verskil spektra induseer en tipe I verskil spektra van natuurlike steroïede inhibeer.
Il. Dui die inhiberende effek van S. frutescens ekstrakte op die katalitiese aktiwiteit
van sitochroom P450-afhanklike-17a-hidroksilase en sitochroom P450-
afhanklike-steroïed- 21-hidroksilase ensieme in skaapbyniermikrosome aan.
III. Beskryf 'n tegniek om die inhiberende effek van S. frutescens op individuele
sitochroom P450-afhankilike ensieme - bobbejaan, skaap en mens sitochroom
P450-afhanklike-17a-hidroksilase, en bees sitochroom P450-afhanklike-steroïed-
21-hidroksilase - in COS 1 selle te bepaal.
IV. Demonstreer dat inhibisie van verhoogde glukokortikoïed plasma konsentrasies
waargeneem in rotte blootgestel aan kroniese immobiliserende stress, moontlik
toegeskryf kan word aan die effek van S. frutescens op die sitochroom P450-
afhanklike ensieme.
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Chapter One
Introduction
The popularity of herbal remedies and medicinal plants has escalated seeing a 380 % rise in the
use of herbal products in the United States from 1990 till 1997 [Eisenberg el al., 1998]. In South
Africa, Sutherlandia frutescens is a highly regarded medicinal plant that has been used for
decades to treat stress and illnesses related to stress [Van Wyk and Wink, 2004; Van Wyk el ai,
1997]. Although most of the therapeutic claims are anecdotal reports, recently there have been
many scientific investigations into the physiological effects of S. frutescens to support these
claims. The scientific validation of the biological effects of medicinal plants is imperative to
ensure the safety and efficacy of its continued use.
Conventional medicines and xenobiotics are metabolized in the liver by the cytochrome P450
system. St John's wort and Ginkgo Milk Thistle, two commonly used herbal remedies, have been
found to interact with cytochrome P450 3A4, a liver P450 enzyme [De Smet, 2002; Marcus and
Grollman, 2002]. Such reports suggest that the use of herbal remedies together with conventional
medicine may compromise, delay or replace an effective form of conventional medicine,
highlighting the importance of the regulation of the use of herbal remedies. Since herbal
remedies are able to interact with the liver P450 enzymes, it may be possible that they also
interact with the steroidogenic cytochrome P450 enzymes of the adrenal. The steroidogenic P450
enzymes catalyse, amongst others, cortisol biosynthesis, the major stress hormone [Lewis, 1996,
2001; Ruckpaul and Rein, 1990]. Thus the aim of this study was to investigate the potential
stress relieving properties of S. frutescens by determining the possible interaction with
steroidogenic cytochrome P450 enzymes, resulting in an inhibition of cortisol biosynthesis.
Stress, be it psychological or physical, activates the hypothalamic-pituitary-adrenal (HPA) axis.
Activation of the HPA-axis leads to an elevation in the concentration of circulating
glucocorticoids, cortisol and corticosterone, and is discussed in Chapter 2. Glucocorticoids are
responsible for maintaining the homeostasis of the central nervous system, metabolism and
immune function. The glucocorticoids released in response to stress also form part of the
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2negative feedback system regulating the HPA-axis. In chronic stress, the negative feedback
regulatory mechanism is overridden and cortisol levels are therefore permanently elevated
[Huizenga et al., 1998]. Long-term exposure to elevated glucocorticoids has been associated
with numerous clinical conditions - hypertension, cardiovascular disease, diabetes, melancholic
depression, osteoporosis, cholesterolemia, visceral fat syndrome and suppression of the
reproductive system, many of which result from a hormone imbalance [Chrousos and Gold,
1998]. A mechanism to alleviate these negative effects arising from the chronic stimulation of
the HPA-axis could employ therapies aimed at decreasing plasma glucocorticoid levels.
Since the cytochrome P450 enzymes are responsible for the biosynthesis of cortisol in the
adrenal gland, inhibition of these enzymes might be a valuable therapy to treat maladies
associated with elevated plasma glucocorticoid levels. TlInesses associated with the
dysfunctioning of the adrenal are treated with cytochrome P450 inhibitors to lower
glucocorticoid and other plasma steroid concentrations [Child et al., 1976; Contreras et al, 1985;
McCance et al., 1987; Nieman, 2002; Verhelst et al., 1991]. The cytochrome P450 enzymes
catalyse adrenal steroid biosynthesis and are considered complex monoxygenase enzyme
systems and are discussed in detail in Chapter 2 [Lewis, 1996]. These enzymes are membrane
bound hemeproteins which when reduced by carbon monoxide and dithionate, demonstrate a
characteristic Soret peak at 450 nm. The enzymes incorporate one atom of molecular oxygen into
their substrate and the other into water. The reaction requires two electrons which are acquired
from NADPH and migrate via redox partners to the cytochrome P450 heme iron. The
cytochrome P450 enzymes employ two different electron transfer chains, dependent on the
location of the enzyme in the cell [Lewis, 1996,2001; Ruckpaul and Rein, 1990]. Cytochrome
P450 enzymes present in the endoplasmic reticulum acquire their electrons from cytochrome
P450 reductase while in the mitochondria, the electron transfer chain comprises adrenodoxin and
adrenodoxin reductase [Takemori and Kominami, 1984]. Adrenodoxin shuttles the electrons to
the P450 enzyme one at a time from adrenodoxin reductase. The complexity of the reactions
catalysed by the P450 enzymes highlights the many possible inhibitory mechanisms that may be
employed. For example, inhibitors may bind to the enzyme and therefore interfere with natural
substrate binding, or the binding of the redox partners which would obstruct the transport of
electrons. Although the steroidogenic P450 enzymes are highly specific for their natural steroid
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3substrates, inhibitors binding to the expressed cytochrome P450 enzymes usually inhibit all the
P450 enzymes in the steroidogenic pathway.
S. frutescens, one of the 3000 plants used for medicinal purposes in South Africa, is discussed in
Chapter 3. Decoctions of the stems and leaves of S. frutescens have traditionally been used to
treat a multitude of physiological afflictions including the symptoms of stress and is currently
considered the most profound adaptogenic tonic [Van Wyk and Wink, 2004; Van Wyk et al,
1997]. Anecdotal evidence of S. frutescens improving the quality of life has resulted in the
marketing of this medicinal plant in tablet form even though there is very little scientific
evidence supporting therapeutic claims or possible implications of its long-term use. Safety and
efficacy issues surrounding herbal remedies and medicinal plants are addressed. The medicinal
value of plants is usually attributed to secondary metabolites and their concentrations which are,
in turn, determined by the environment. Traditional healers have identified, by trial and error, not
only which plants have medicinal properties but also which parts of the plants contain the active
compounds required for healing purposes. Some of the compounds that have been identified in S.
frutescens include L-canavanine, pinitol, gamma-amino butyric acid, various flavonoids and
triterpenoids which may contribute toward some of the positive anecdotal effects that have been
reported. Current research into the pharmacological effects of S. frutescens and claims of anti-
HIVand anti-cancer properties, which sparked scientific investigations into the medicinal
potential of S. frutescens, are presented.
In Chapter 4 the investigation into the bioactivity of S. frutescens is presented. Aqueous and
methanol extracts of S. frutescens, bioactive compounds as well as commercially available
tablets were investigated for possible interactions with the steroidogenic P450 enzymes. Due to
the unique spectral properties of the cytochrome P450 enzymes, interactions with these enzymes
can be monitored by UV spectrometry. Two spectral assays were carried out to determine if the
test components could firstly, bind to the P450 enzymes and secondly, influence the binding of
natural steroid substrates. The influence of the S. frutescens on the catalytic activity of the P450
enzymes was subsequently investigated in vitro and in COS I cells as was the inhibitory effect of
test components on the catalytic activity of mitochondrial and microsomal cytochrome P450
enzymes. These assays were augmented by investigations of S. frutescens' inhibitory effects on
17a-hydroylaseI17,20 lyase and 21-hydroxylase expressed in COS 1 cells.
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4The anti-stress properties of S. frutescens may be attributed to more than just one compound
present in the plant which could influence the release and lor synthesis of the glucocorticoids at
various levels of the HPA-axis. In order to scientifically appraise the stress relieving properties
of S. frutescens, plasma glucocorticoid concentrations were monitored in rats subjected to
chronic immobilization stress, in the absence and presence of administered S. frutescens [Smith
and Myburgh, 2004]. Chapter 5 reports that rats treated with S. frutescens exhibited lower
plasma glucocorticoid concentrations in response to chronic stress compared to the control rats
receiving a placebo. The plant may thus alleviate the symptoms of stress by decreasing the
circulating glucocorticoid levels. The mechanism of action may be, amongst others, through the
inhibition of the steroidogenic cytochrome P450 enzymes which catalyse the biosynthesis of
glucocorticoids.
Chapter 6 summanses the findings and concludes this study of the investigations into the
bioactivity of S. frutescens.
Stellenbosch University http://scholar.sun.ac.za
5Chapter Two
The role of adrenal steroidogenesis in the regulation of the HPA-axis
and stress response
Stress can be defined as any perturbation of homeostasis and is stimulated by a stressor. The
stressor, which is defined as an event that elicits stress, may be either psychological stressors like
major life events, trauma and environmentally related factors, or physical stressors which include
pathogens and toxins. Both types of stressors activate the hypothalamic pituitary adrenal (HPA)
axis stimulating the increased production of cortisol by the adrenal gland. Acute stress results in
temporarily elevated cortisol plasma levels while chronic stress is associated with permanently
elevated cortisol concentrations.
It has been known for thousands of years that psychological stress can affect the outcome of
disease and was first recorded by Galen in 200AD [Dunn, 1996]. The detrimental effects of
stress on the outcome of disease may be attributed to chronic elevated cortisol levels. It has been
proposed that chronic exposure of physiological systems to repeated elevation of cortisol could
impact markedly on homeostasis and health [Chrousos and Gold, 1998; Reiche et al., 2004;
Seeman et al., ]997]. The stress response, the biosynthesis of cortisol in the adrenal gland
catalysed by the cytochrome P450 enzymes as well as the effects of stress, will be explored in
this chapter.
2.1 The HPA-axis
The HPA-axis is activated in response to either physical or psychological stress, invariably
leading to elevated levels of the glucocorticoid hormone, cortisol, secreted from the adrenal
cortex [Munck et al., 1984; Traustadóttir et al., 2005; Vander et al., 2001]. The function of the
HPA-axis is to maintain basal and stress related homeostasis of the central nervous system,
cardiovascular, metabolic and immune function [Chrousos, 1998]. Physical stress includes fever,
surgery, burn injury, hypo- and hyperglycaemia, hypo- and hypertension and exercise.
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6Psychological stress is different to physical stress in that there is no clear beginning or end and it
is not linked to an increase in metabolic demand. It is not only the HPA axis but also the
sympatic nervous system (noradrenergic system controlling autonomic outputs) which is
activated by stress as illustrated in Figure 1 [Chrousos and Gold, 1998; Haas, 2001; Moyniham,
2003; Reiche et al., 2004; Sved et al., 2002; Vander et al., 200 I; Young et al., 2005].
Neurosensory signals are ultimately processed in the nucleus of both the hypothalamus and the
locus coeruleus-noradrenergic centre. The paraventricular nucleus (PYN) of the hypothalamus is
first to respond to the positive signal for the secretion of cortisol. Specialized neurons of the
PYN project into the median eminence of the hypothalamus. Axonal processes subsequently
form special junctions with the capillaries of the pituitary. The PYN produces, corticotrophin
releasing hormone (CRH), a neuropeptide, which is carried by the portal vein to the anterior
pituitary stimulating corticotroph cells to produce the complex pro-opiomelanocortin (POMC)
proteins [Vale et al., 1981]. POMC is cleaved to form adrenocorticotropic hormone (ACTH),
beta-endorphin and other peptide hormones [Guillemin et al., 1977]. When the ACTH reaches
the adrenal cortex, the rate of cortisol biosynthesis and secretion is increased, and cortisol is
subsequently released into the blood stream. During times of stress there is not only an increase
in CRH, ACTH and cortisol, but also a significant increase in cholesterol levels since it is the
substrate for cortisol biosynthesis in the adrenal glands.
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Figure 1. Stress response and the interactions between the nervous, endocrine and immune system. The
hypothalamic factors regulate the pituitary cells and the sympathetic nervous system. The glucocorticoids
specifically cortisol, inhibit the production of corticotrophin-releasing factor (CRF, corticotrophin releasing
hormone CRH) and adrenocorticotropic hormone (ACTH). + stimulation, - inhibition [reproduced from
Reiche et al., 20041.
Activation of the sympathetic nervous system by either physical or psychological stress, results
in the secretion of the catecholamines, epinephrine and norepinephrine, from the adrenal medulla
into the blood (Figure 1). This response is more commonly known as the fight-or-flight response
where an immediate physical response is required to prevent bodily harm. Epinephrine increases
the rate and depth of respiration, mobilizes glucose as a source of energy and increases the heart
rate and cardiac output. Norepinephrine is a potent vasoconstrictor, maintains blood pressure and
also increases the rate and depth of respiration [Reiche et al., 2004; Saunders, 2003; Vander et
al., 2001]. Receptors for the catecholamines are present in smooth muscle, cardiac muscle,
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8adrenal gland cells and specific central nervous system neurons [Vander et al., 200 I]. The locus
coeruleus, a nucleus in the brain stem pons, contains noradrenergic neuronal cell bodies. These
neurons provide a stimulatory noradrenergic input to the PYN activating the HPA axis [Young et
al., 2005; Sved et al., 2002]. Smagin et al. (1995) have suggested that norepinephrine may
regulate the release of CRH from the hypothalamus. Furthermore, the catecholamines also
regulate the secretion of hormones from the adrenal as well as the expression of some
cytochrome P450 enzymes responsible for catalyzing the biosynthesis of adrenal steroids
[Smagin et al., 1995].
The hippocampus and amygdale can influence the HPA axis via the PYN [Felman et al., 1995].
The hippocampus is a malleable brain structure that is sensitive to the effects of stress and
trauma and is important for certain types of memory and learning. During hippocampal
formation, high levels of adrenal steroid receptors are expressed [McEwan, 2005]. It is known
that adrenocortical hormones have a wide variety of effects in the brain and these hormones have
been linked to dendritic shortening [De Kloet et al., 1998; McEwan, 2003; McEwan, 2004].
2.1.1 The Adrenal Gland
Activation of the HP A-axis results in the release of cortisol from the adrenal glands. The adrenal
glands lie above the kidney and express the enzymes responsible for the production of steroids -
3p-hydroxysteroid dehydrogenase (3PHSD) enzyme and five cytochrome P450 enzymes;
cytochrome P450 side chain cleavage (CYP llA I), Il p-hydroxylase (CYP lIB 1), aldosterone
synthase (CYPIIB2), 17a-hydroylaseIl7,20 lyase (CYPI7) and 2I-hydroxylase (CYP2I). The
adrenal gland can be divided into two distinct zones; the cortex and medulla, where the medulla
occupies the centre of the gland and makes up approximately one quarter of the adrenal mass.
The medulla contains two distinct cell types, the norepinephrine secreting cells, which are small,
dense granules and the epinephrine secreting cells, which are larger, less dense granules. The
medulla chromaffin cells have been identified in the cortical region and similarly cortical cells
have been identified in the medulla. This distribution of the cells within the adrenal provides
extensive contact areas, enhancing paracrine signalling which influences adrenal steroidogenesis.
The catecholamines secreted from the medulla stimulate the secretion of cortisol, aldosterone
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9and androstenedione from the adrenocortical cells. Furthermore, the catecholamines have
stimulatory effects on the transcription of some cytochrome P450 genes [Guse-Behling et aI.,
1992].
The adrenal cortex consists of three zones; zona glomerulosa, zona fasciculata and the zona
reticularis (Figure 2). The mineralocorticoids are produced and secreted by the glomerulosa cells.
Androgens and glucocorticoids are produced in the remaining two zones. CYP17 is not
expressed in the zona glomerulosa, but is expressed in the zona fasciculata and to a lesser extent
in the zona reticularis. CYP21 is located in all three zones of the adrenal cortex [Inano et aI.,
1969]. Cortisol production takes place primarily in the zona fasciculata but also in the zona
reticularis while it is not produced in the zona glomerulosa due to the lack of CYP17 expression
in this zone. Aldosterone synthase (CYPllB2) is expressed only in the zona glomerulosa and
aldosterone is therefore the only hormone of physiological significance secreted by the zona
glomerulosa.
,..,..---' - --
P450s I Hormones
expressed I secreted
11A, 11B1, ,Androgens ~nd
17,21 glucocorticolds
I
I
11A.11B1, !Androgens and
17.21 glucocorticolds
Figure 2. Cross section of the adrenal gland showing the adrenal cortex (C) and adrenal medulla (M). The
three zones of the adrenal cortex are illustrated on the right together with the P450 enzymes expressed and
the hormones secreted from these regions [modified from Young and Heath, 2000].
Both the medulla and adrenal cortex are innervated by a rich nerve supply that synapses directly
with the steroid producing cells [Vinson et al., 1994]. Both endocrine and neural activities
control adrenal activity. Many different neurotransmitters have been shown to be involved in
relaying signals to the endocrine steroid producing cells. The catecholamines and acetylcholine
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are two of the neurotransmitters secreted to the adrenal cortical cells. The regulation of this
neural component that controls adrenal steroidogenesis is complex and not well understood
[Vinson et al., 1994] but its role is most likely involved in the fine-tuning of adrenal
steroidogenesis.
2.1.2 Physiology of Cortisol
The glucocorticoids, specifically cortisol in humans and corticosterone in rats, which are released
in response to stress, play an important role in the stress response. Cortisol influences organic
metabolism in mobilising fuels by increasing plasma concentrations of amino acids (source of
glucose via gluconeogenesis and available for tissue repair if damage was incurred), glucose,
glycerol and free fatty acids. Cortisol has also been shown to increase vascular reactivity [Munck
et al., 1984; Seeman et al., 1997; Traustadóttir et al., 2005] and has immunosuppressive effects
on lymphocytes and macrophages. Glucocorticoids decrease the production of many cytokines,
mediators of inflammation, and decrease effects of some inflammatory molecules on the target
tissue [Chrousos and Gold, 1998; Hassig et al., 1996; Kunz-Ebrecht et al., 2003; Maes et al.,
1998; Moyniham, 2003; Reiche et al., 2004; Vander et al., 2001]. These effects of cortisol
protect against damage from excessive inflammation [Vander et al., 2001]. The primary function
of the glucocorticoids in the stress response is therefore to protect the body from its own defence
mechanisms. The cortisol response is vital since without it an individual may expenence
circulatory failure and possible death [Munck et al., 1984; Vander et al., 2001].
Basal cortisol concentrations vary In a circadian rhythm as illustrated in Figure 3. Cortisol
concentrations peak after waking, with a 50-70 % increase in cortisol levels within half an hour
of waking, and are lowest just before sleep [Pruessner et al., 1997]. The basal levels of cortisol
range between 165-690 nmol/l. Unbound cortisol is biologically active and 3.8 % of plasma
cortisol is normally unbound [Pruessner et al., 1997]. Under normal conditions, the average
plasma cortisol concentration in human adults at 8 a.m. is 358 nmol/I at a secretion rate of 15
mg/day while during severe stress the maximal rate of cortisol secretion is 300-400 mg/day
[Saunders, 2003]. Chronic stress results in sustained increased cortisol plasma concentrations
(Figure 3) [Chrousos, 1998; Chrousos and Gold, 1998; Weber et al., 2000]. Increased
Stellenbosch University http://scholar.sun.ac.za
11
susceptibility to infectious disease has been associated with persistent elevations of cortisol
concentrations. Cortisol concentrations are related to gender as the cortisol responsivity in
females changes during the menstrual cycle. On the other hand, cortisol concentrations are not
related to age, weight, smoking status, or alcohol consumption (the night prior sampling)
[Pruessner et al., 1997]. Interestingly another study [Traustadóttir et al., 2005] has indicated that
amongst unfit women, ageing is associated with increased reactivity of the HPA-axis, indicating
that exercise might be an effective way of modifying neuroendocrine changes associated with
agmg.
P
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I DARK I
8 p=m~----~8 am
Figure 3. Circadian pattern of cortisol secretion in nonstressed (NS solid line) and chronically stressed (CS
dotted line) individuals Ireproduced from Chrousos and Gold, 19981
fn humans, steroid hormones circulate in the plasma mainly bound to proteins - sex hormone
binding globulin (SHBO), corticosteroid binding globulin (CBO) and albumin [Dunn et al.,
1981]. SHBO and CBO are both highly specific and have low binding capacities whereas;
albumin is a non-specific steroid binding protein with a high binding capacity, functioning as a
reservoir for circulating steroids. Deoxycortisol, corticosterone and cortisol are the main
physiological ligands for CBO and all bind with similar binding affinity while the androgens
bind with low affinity [Dunn et al., 1981]. SHBO has a high affinity for the androgens
dehydroepiandrosterone (DHEA). Of the average 400 nM cortisol present in the plasma,
approximately 89.7 % is bound to the CBO and 6.3 % is bound to albumin while 3.8 % is
unbound [Dunn et al., 1981; Louw, 1998]. The binding of cortisol to the plasma proteins
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increases its half-life. The plasma concentrations of the binding proteins fluctuate independently
throughout life for development and maturation of cellular functions, but may also be altered in
specific disease states. The free versus bound ratio is not constant and free cortisol can vary up to
200 % from the minimum value when the total CBGs only decrease a maximum of 25 % [Dunn
et al., 1981; Saunders, 2003]. When the CBG concentration is increased, there is an increase in
cortisol bound to the CBG and a decrease in the percent of unbound cortisol to alleviate the
suppressing effects of glucocorticoids on the release of ACTH from the pituitary [Dunn et al.,
1981; Louw, 1998].
The circulating cortisol makes its way through the kidney into unne as well as through the
parotid gland into saliva. Furthermore, cortisol crosses the blood brain barrier where it is able to
reach all parts of the central nervous system (CNS). Cortisol enters the cerebrospinal fluid via the
choroids plexus to gain access to the regulatory sites on the amygdala, hippocampus and
hypothalamus. Access to the anterior pituitary is gained through systemic circulation [Saunders,
2003]. Munck et al. (1984) stated that the physiologically important effects associated with
glucocorticoids, are not simply a consequence of primary action exerted by the steroid on the
target tissue, but rather the secondary effect, which employs various intercellular mediators
resulting in the desired response. The mechanisms through which glucocorticoids act involve the
glucocorticoid receptors (GRs) and the mineralocorticoids receptors (MRs) and may require
RNA and protein synthesis [Munck and Brinck-Johnson, 1967]. Since the adrenal steroids have
receptors in all nucleated cell types, cortisol is able to cross membranes and to bind to receptors
in the cytoplasm and enter the nucleus, where its main function is to either inhibit or induce the
transcription of a wide range of genes [Saunders, 2003]. Access to the receptors is regulated by
the circulating concentration of steroid hormones, corticosteroid binding globulins, the density of
the two receptor types and by the enzyme Ll-jl-hydroxysteroid dehydrogenase (LI PHSD)
[Weber et al., 2000]. Cortisol is converted to its inactive form cortisone and visa versa by
lIpHSD in the liver. The liver is the principal site for glucocorticoid catabolism where cortisol is
broken down and conjugated to glucuronic acid, a soluble product which is excreted in the urine.
The liver is responsible for degrading 15 % of the secreted cortisol, which is excreted in the
stool. The CYP3A family of enzymes is the most abundant group of P450 enzymes in the liver.
The CYP3A enzymes metabolize fat soluble hormones including cortisol and estrogens and these
enzymes are thus responsible for clearing cortisol from the system. Cortisol is converted to 6p-
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hydroxycortisol by CYP3A and the measurement of urinary 6~-hydroxycortisol has widely been
used as a non-invasive clinical test to detect cytochrome P4S0 induction. Abel et al. (1992),
however, demonstrated the highly complex and variable hepatic metabolism of cortisol by
identifying a myriad of metabolites of cortisol including 6a- and 6~-hydroxycortisol, 20~-
dihydroxycortisol, 20~-dihydroxycortisone, cortisone and 3a- and 3~-tetrahydrocortisone and
others, suggesting that the analysis of CYP3A activity in man is limited when only 6~-
hydroxycortisol excretion is measured.
DHEA is another major steroid produced by the adrenal and acts as a functional antagonist of
cortisol. The concentration of DHEA in human adult plasma is 0.01 flM to 0.02 flM [Kalimi et
al., 1994]. DHEA is a C 19 steroid classified as an androgen, which has anti-glucocorticoid
effects, namely, anti-stress, anti-diabetic, anti-ageing. DHEA has been shown to boost the
immune system and improves memory by protecting brain neurons, thereby blocking the
deleterious effects of cortisol during stress [Kalimi et al., 1994]. DHEA levels do not increase in
response to acute stress. However, Heuser et al. (1998) found that in severely depressed patients,
which is understood as a chronic stress condition, both cortisol and DHEA were hyper secreted
in a circadian pattern, suggesting a possible adaptive cortisol-antagonizing effect in chronic
stress [Heuser et al., 1998].
2.1.3 Regulation of the HPA-axis
Three pnmary structures regulate the secretion of adrenocortical glucocorticoids by negative
feedback, namely, the pituitary gland, the hypothalamus and the hippocampus [Jacobson, 1991;
Young et al., 2005]. The hypothalamus receives a wide array of both chemical and electrical
stimuli to sense the homeostasis of the organism. In response to stimuli, the hypothalamus
generates both chemical and electrical signals and is thus the centre for integrating the nervous
and endocrine systems. The activity of the adrenocortical system increases in a circadian rhythm,
and more significantly so in response to stress [Jacobson and Sapolsky, 1991; Lovallo, 2000].
Sites for the negative feedback are mostly identified by the presence of corticosteroid receptors.
GRs are abundant in the limbic system (lateral septum), central amygdale, dentate gyrus of the
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hippocampus and the noradrenergic neurons in the locus coeruleus. These glucocorticoid
receptors are targets for cortisol and possible targets for negative feedback on stress-activated
brain mechanisms [Reul and De Kloet, 1985]. Both glucocorticoid- and mineralocorticoid
receptors have been located in the hippocampus which expresses the highest levels of these
receptors compared to other regions in the brain. The hippocampus is therefore considered the
focal point for the regulation of the activity of the HPA-axis. GRs can bind only glucocorticoids,
whereas MRs, which have a higher affinity for glucocorticoids, can bind both glucocorticoids
and mineralocorticoids [Reul and De Kloet, 1985]. The role of the hippocampus in regulation of
the HPA-axis was reviewed by Jacobson and Sapolsky (1991) and they suggest that the
hippocampus regulates the activity of the HPA, most significantly by inhibiting the secretion of
ACTH [Dallman et al., 1987; McEwan, 1997; Saunders, 2003].
ACTH secreted by corticotropes in the anterior pituitary drives the release of cortisol from the
adrenal cortex. ACTH secretion is regulated by factors (CRH, vasopressin, oxytocin,
epinephrine) secreted from neurons in the hypothalamo-hypophysial portal circulation [Jacobson
and De Kloet, 1991; Plotsky, 1985]. The activity of the HPA-axis is reduced by suppression of
the CRH gene by mechanisms sensitive to cortisol concentration [Jacobson and De Kloet, 1991;
Munck et al., 1984]. Cortisol therefore has a negative feedback effect on the release of CRH
from the hypothalamus and is illustrated in Figure I. In addition, POMC (which is cleaved to
form ACTH and ~-endorphin) biosynthesis is rapidly reduced as a result of decreased CRH,
resulting in decreased ACTH levels. The POMC gene is an additional negative feedback target
as it contains a negative glucocorticoid response element (nGRE) to which cortisol (bound to the
GR) binds, inhibiting POMC synthesis which, in turn, inhibits the production of ACTH [Drouin
et al., 1993; Slabbert, 2003]. Regulation of adrenocortical activity also takes place within the
adrenal (intra-adrenal activity) as ACTH is not only derived from the anterior pituitary but is also
produced by the adrenal [Markowska et al., 1993]. Furthermore, CRH expression has been
shown in the adrenal gland and has direct effects on the activity of the adrenal [Bornstein et al.,
1990]. ACTH has an acute and chronic effect on the adrenal resulting in the stimulation of
steroidogenesis and growth. An acute response stimulates steroidogenesis through a
steroidogenic acute regulatory (StAR) protein mediated increase in cholesterol. StAR stimulates
the mobilization of cholesterol from lipid stores to the inner mitochondrial membrane and thus
increases the availability of cholesterol for steroid hormone biosynthesis. The chronic effect of
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ACTH increases the synthesis of all steroidogenic cytochrome P4S0 enzymes and adrenodoxin
reductase. ACTH binds to a G protein-coupled melanocortin-2 receptor on adrenocortical cells
which activates adenylate cyclase producing cAMP from ATP. cAMP-dependent protein kinase
(PKA) is subsequently activated resulting in the release of catalytic subunits which activate the
synthesis and activity of enzymes by phosphorylation [Lewis, 2001; Lisurek and Bernhardt,
2004; Waterman and Bischof, 1997]. Angiotensin II, cytokines and Ca ++, are some of the many
additional factors also involved in the regulation.
2.1.4 Adverse effects associated with chronic exposure to elevated cortisol levels
Activation of the stress response by a psychological event is not simply a response to the stimuli.
The reaction to the stressor is determined by the individual's perception of, and interaction with
the stressor, since individuals respond to similar situations or stress differently [Lovallo, 1997;
Saunders, 2003]. The repeated delivery of stress, which includes psychological, chemical or
physical stress, may lead to drastic changes in the physiology of neural endocrine, immune and
digestive systems [Ha et al., 2003].
Acute stress refers to temporary elevated plasma cortisol levels, after which the cortisol levels
and activity of the HPA-axis return to basal conditions. Excessive or chronic stress would result
in permanently elevated plasma cortisol levels and the homeostasis would have to be re-
established, a phenomenon known as allostasis [Seeman et al., 1997]. Allostasis of the nervous
system, HPA-axis, metabolism, cardiovascular and immune system is brought about by the
catecholamines and the glucocorticoids. The glucocorticoid hormones, catecholamines and the
pro-inflammatory cytokines are the principal messengers for communication between the central
nervous system and the immune system [Maes et al., 1998; Reiche et al., 2004]. Young et al.
(2005) concluded that the noradrenergic system can influence the magnitude of the HPA-axis
response to stress, but in major depression, activation of the HPA-axis appears autonomous of
the noradrenergic influence. A prolonged stress response and the sustained activity of the HPA-
axis together with persistent increases in cortisol production, have been associated with
depression, hypertension, osteoporosis, immunosuppression [Chrousos and Gold, 1998; Hassig
et al., 1996; Kunz-Ebrecht et al., 2003; Maes et al., 1998; Moyniham, 2003; Seeman et al., 1997;
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Reiche et al., 2004], visceral obesity and insulin resistance [Hautanen and Adlercreutz, 1993;
Rosmond et al., 1998]. There has also been substantial evidence suggesting that prolonged stress
results in an increased risk of chronic conditions such as, cardiovascular disease, diabetes and
atherosclerosis [Bjomtorp, 1997; Chrousos and Gold, 1998).
Human [Kunz-Ebrecht et al., 2003; Maes et al., 1998] and animal [Sklar and Anisman, 1979]
studies have suggested that stress renders these subjects more susceptible to disease and impairs
the functioning of the immune system and this topic has been reviewed by many researchers
[Chrousos and Gold, 1998; Hassig et al., 1996; Reiche et aI., 2004]. Chronic stress significantly
suppresses the immune response of blood and spleen lymphocytes, T-cell mitogenesis,
phagocytosis, Natural killer (NK) cell activity and production of inflammatory cytokines,
interleukin 2 and interferon y [Chrousos and Gold, 1998; Hassig et al., 1996; Kunz-Ebrecht et
al., 2003; Maes et al., 1998; Moyniham, 1989 & 2003; Munck et al., 1984; Reiche et al., 2004).
Studies investigating different stressors and species have shown variable results since the
interpretation of the response to stressors vary between humans and/or animals - different aspects
of the immune response are inhibited, demonstrating the complexity in communication between
the brain, the immune system and behaviour. Different experimental designs of studies and
immunological assays, forms of depression assessment and age of individuals are important
factors involved in the variability, which have to be taken into account when interpreting the
results.
Maes et al. (1998) investigated the effect of psychological stress on the Th-I-l ike response and
found that elevated plasma cortisol levels are associated with an increased response. The Th-l
response involves the secretion of IFN-y and IL-2, which are involved in cellular immune
functions, whereas the Th-2-like response involves the secretion of IL-4 and IL-5 thus enhancing
humoral immune reactions associated with B cells. IL-4 and IL-lO suppress Th 1 effector
functions [Maes et al., 1998; Hassig et al., 1996]. Increased plasma cortisol levels result in a
long-lasting suppression of cellular immune reactions associated with T-cells and thus increase
in susceptibility to infection [Hassig et al., 1996]. Reiche et al. (2004) summarized the effects of
the stress hormones on the immune system illustrated in Figure 4.
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The progression of HIV infection is also accompanied by alterations in the production of the
adrenal steroids [Clerici 1997]. HIV patients exhibit increased cortisol and decreased DHEA
plasma levels [Chrousos 1998, Clerici et al., 1997]. It has been reported that DHEA can act as a
functional antagonist of the immunoregulatory activities of cortisol [Heuser et al., 1998].
Elevated cortisol levels inhibit IL-I and the transcription of IL-2 and IFNy genes but not the
transcription of IL-4 [Clerici et al., 1997]. Thus, individuals experiencing chronic stress may be
more susceptible to disease as a result of the inhibition of the immune response .
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Figure 4. Systemic effects of glucocorticoids and catecholamines on the immune system. NK, natural-killer
cells; MD, macrophage; Thl, T'-helper lymphocyte type 1 cells; Th2, T-helper lymphocyte type 2 cells; TNF,
tumor necrosis factor [Reproduced from Reiche et al., 20041.
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Cancers associated with DNA tumor virus are more likely to be affected by psychological stress
than cancers induced by chemical carcinogens. It is possible that stress and depression foster
tumor expression since increased cortisol production associated with stress is able to inhibit
various aspects of the immune system. Stress therefore compromises some of the important
effectors of the immune response against tumors [Munck et al., 1984, Reiche et al., 2004].
Kiecolt-Glaser et al. (1985) concluded depressed or stressed patients showed significantly
decreased DNA repair of damaged DNA as compared to less stressed patients. Levav et al.
(2000) showed that the incidence of cancer was increased in parents of accident victims, as
compared to parents who had not lost offspring. After a twenty year follow up on the patients it
was noted that the risk of death (as apposed to the progression of cancer) was increased if the
patient was diagnosed before their loss [Levav et al., 2000]. These findings indicate that stress
may render an individual more susceptible to cancer and, in addition, severe stress experienced
after being diagnosed with cancer, could result in increased progression of the disease and thus
increased mortality.
The stress hormones, which include the glucocorticoids and catecholamines, can also modulate
brain function by changing the structure of the neurons in the hippocampal formation [McEwan,
2005]. The dendrite gyrus, within the hippocampus is most vulnerable to some types of acute and
chronic stressors. These stressors suppress neurogenesis or cell survival in the dendrite gyrus
[McEwan, 1997,2003 & 2005]. The CA3 region of the hippocampus is connected to the dendrite
gyrus and it has been documented that chronic stress causes retraction and simplification of the
dendrites in this region. Thus far the remodelling of the hippocampus which occurs in response
to stress has been found to be largely reversible over a three week period [McEwan, 2003].
However, it is possible that sustained stress may cause more permanent damage. Furthermore it
is important to note that the hippocampus may be more vulnerable in sustained stress situations if
the mechanisms activated in response to stress were not in place [McEwan, 2003 & 2005]. The
prefrontal cortex and amygdale are also influenced by stress, since repeated stress has resulted in
dendritic shortening in the prefrontal cortex and conversely, dendritic growth in neurons of the
amygdale [McEwan, 1997, 2003 & 2005]. Roelofs et al. (2005) have recently suggested that
increased cortisol levels are also associated with diminished active approach avoidance
behaviour with subjects showing slower avoidance actions to threatening stimuli in times of
increased stress.
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Chronic restraint stress has a potent significant effect on the gene expression profile in rat liver
[Ha et al., 2003]. Genes altered most significantly included those involved in lipid metabolism
and detoxification. Chronic stress suppressed the uptake of glucose from peripheral tissue and
the immune response. In addition, fat stored energy was mobilized and gluconeogenesis
stimulated. Although the exact mechanism whereby stress stimuli was able to trigger these
metabolic and physiological changes, remains uncertain, these results suggest that these changes
may be associated with the altered gene profile [Ha et al., 2003].
In summary, evidence from animal and human studies strongly suggests that persistent stress and
depression result in impairment of the immune response as well as an increased susceptibility to
the onset of cancer and other diseases. There are many conflicting reports due firstly, to the
diversity of the experimental approaches and secondly, the diversity of individuals studied.
Although these adverse effects of stress cannot as yet be attributed to a specific factor of the
stress response, cortisol does appear to be a key player [Dimsdale and Herd, 1982; Segerstrom,
2003]. Cortisol biosynthesis takes place in the adrenal gland and the reactions are catalysed by
the steroidogenic cytochrome P450 enzymes.
2.2 Adrenal Steroidogenesis
The adrenal gland secretes the mineralocorticoid, glucocorticoid and androgenic steroid
hormones. Mineralocorticoids regulate the water and sodium/potassium balance in the body.
Mineralocorticoid action results in the absorption of sodium from urine, sweat, saliva and gastric
juices. Glucocorticoids playa significant role in the regulation of protein, carbohydrate and lipid
metabolism, while the androgens are required for the functional development of secondary sex
characteristics. The reactions involved in steroid hormone biosynthesis are primarily of the
monooxygenase type, catalyzed by various cytochromes P450 enzymes [Ruckpaul and Rein,
1990]. The catalytic reactions involved in corticosteroid biosynthesis include: hydroxylations, C-
C bond cleavages, dehydrogenation, isomerization and oxidation reactions. Reactions in the
steroid hormone biosynthesis pathway (Figure 5) are catalyzed in the mitochondria and
endoplasmic reticulum of the adrenal cortex, by the cytochrome P450 enzymes and 3~-
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hydroxysteroid dehydrogenase (3~HSD). The mitochondria contain cytochrome P450 side chain
cleavage (CYP Il A), cytochrome-ll ~-hydroxylase (CYP 11BI) and aldosterone synthase
(CYPIIB2), which are associated with the inner mitochondrial membrane. Cytochrome P450
21-hydroxylase (CYP21) and cytochrome P450 17-a-hydroxylase/17,20 lyase (CYP17) are
embedded in the endoplasmic reticulum [Hall, 1986; Lisurek and Bernhardt, 2004; Machino et
al., 1969; Payne and Hales, 2004; Ruckpaul and Rein, 1990; Takemori and Kominami, 1984].
The metabolic intermediates move back and forth between the endoplasmic reticulum and
mitochondria with the initial and final reactions of steroidogenesis taking place in the
mitochondria. The four major P450 species are integral membrane proteins, embedded in the
organelles and their substrate binding site faces the lipid phase.
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Figure 5. Steroid biosynthesis in the adrenal cortex Ireproduced from Lisurek and Bernhardt, 20041.
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2.2.1 Cytochrome P450
Garfunkel (1958) and Klingenburg (1958) were the first to discover the heme-thiolate proteins
and in 1964 [Omura and Sato, 1964] the carbon monoxide binding pigment of liver and adrenal
mierosomes was named cytochrome P450, and shown to be monooxygenases involved in the
oxidation of drugs and steroids. These cytochrome P450 enzymes, most abundant in the liver, are
predominantly found in the endoplasmic reticulum and mitochondria. Levels of these enzymes in
the liver as well as in other organs are variable and can differ as a result of chemical induction,
genetic variation and dietary habits, age, gender, etc [Lewis, 1996 & 2001]. The cytochrome
P450 enzymes are distributed in all five kingdoms, with the exception of a primitive bacterial
species. The enzymes are present in a variety of organs and tissues - kidney, the lungs, the skin,
the adrenal gland, the spleen, ovaries, testis, placenta and brain. The cytochrome P450 enzymes
differ from the other cytochromes (cytochrome a, b, c) in that their purpose is not solely for
electron transfer through a redox potential gradient, but rather for the activation of a dioxygen
molecule with the subsequent insertion of a single oxygen atom into the substrate [Lewis, 1996
& 2001; Ruckpaul and Rein, 1990]. Peroxygenation, hydroxylation, epoxidation, deamination,
desulfuration, dehalogenation and reduction are some of the various reactions catalyzed by
cytochrome P450 enzymes. The reactions have a wide range of physiological functions including
drug metabolism, detoxification of carcinogens and xenobiotics, metabolism of fatty acids, bile
acids, Vitamin D and the metabolism of steroids. The interaction of cytochrome P450 with
xenobiotics is a detoxication process but may in some cases, however, result in a product with
higher toxicity. Liver mierosomes contain P450 enzymes involved in detoxifying xenobiotics
and these enzymes often have broad and overlapping substrate specificities whereas those P450
enzymes involved in steroid biosynthesis in the adrenal glands are far more selective in their
choice of substrate.
Mechanisms of Cytochrome P450 Catalyzed Reactions
The reactions catalyzed by the cytochrome P450 enzymes require a transfer of electrons from
NAD(P)H either via cytochrome P450 reductase in the endoplasmic reticulum, or via ferredoxin
reductase in the mitochondria. The electron is subsequently transferred to the cytochrome P450
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which results in reductive activation of molecular oxygen - one oxygen atom is inserted into
the substrate (ROH) and the other into H20, shown in Figure 6.
RH + O2---, ROH + H20
2e-
Figure 6. Reactions mediated by the P450 enzymes involve the conversion of an organic substrate (RH), in the
presence of oxygen, to a mono-oxygenated metabolite (ROH) and water.
The reducing equivalents required for the reaction to proceed are supplied by NADPH and less
often by NADH. Substrate binding causes a conformational change in the P450 enzymes which
triggers the interaction of the P450 enzymes with their redox partners [Lewis, 1996 & 2001].
The reducing equivalents are transferred in two stages from NAD(P)H via one or 2 redox
partners. The spin state of cytochrome P450 does not dramatically affect electron transfer from
NADPH via the reductase but substrate is required for efficient electron transfer (Kominami and
Takemori, 1982; Ruckpaul and Rein, 1990). The cytochrome P450 enzymes are broadly
classified in two classes based on the electron transfer system they employ.
NADPH
(b)
NADPH
NADP
Figure 7. Schematic representation of the steroidogenic electron transfer system of mitochondria (a) and
mierosomes (b). Oxidized adrenodoxin (AdO), reduced adrenodoxin (Ad'), substrate (S) [reproduced from
Takemori and Kominami, 19841.
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The mitochondrial cytochrome P450 enzymes are considered as Class I P450 enzymes since they
require both a FAD containing reductase, adrenodoxin reductase (ADXR), and an iron sulphur
protein/ferrodoxin, adrenodoxin (ADX), to transport the reducing equivalents (Figure 7a). The
ADX forms a tightly associated bimolecular complex with the ADXR. The flavin moiety is
reduced by NADPH and the electron is transferred from ADXR to the oxidized ADX which,
upon reduction, dissociates from ADXR. The reduced ADX subsequently associates with the
substrate-bound cytochrome P450. The electron gained by the P450 enzyme is used in the
hydroxylation reactions. The transfer of electrons thus involves sequential complex formations of
ADXR and ADX with the cytochrome P450, with the ADX molecule in the mitochondrial
electron transfer chain 'shuttling' the electrons between the ADXR and the cytochrome P450
enzyme [Ziegler et al., 1999]. The microsomal P450 enzymes, categorized as Class II
cytochrome P450 enzymes, require cytochrome P450 reductase to transfer the reducing
equivalents directly from NADPH (Figure 7b). The reductase molecule is embedded in the
membrane and contains a FAD! FMN moiety. Six to eight cytochrome P450 enzymes tend to
cluster around a central reductase [Nebert et al., 1982; Ziegler et al., 1999].
The reduction of dioxide in the P450 system is carefully regulated by the redox partners, the
medium which would be either membrane bound or cytosolic, the nature of the active site and its
degree of solvation as well as the influence of the heme-thiolate group of the enzyme.
Uncoupling of the reaction occurs if this regulation is not tightly controlled, resulting in the
release of reactive oxygen species [Lewis, 2001].
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Figure 8. Cytochrome CYPIOl catalytic cycle. The steps represented in the figure are discussed in the text.
In the first stage of the cytochrome P450 catalytic cycle [Hall, 1986; Lewis, 2001; Porter and
Coon, 1991; White and Coon, 1980] the enzyme is in its resting state during which the heme iron
(Fe(lll)) is in a low-spin state and the sixth distal ligand is most likely water or a hydroxyl ion
(Figure 8). The substrate binds to the heme opposite the fifth ligand (Step I), prompted by the
hydrophobic attraction of the substrate for the heme pocket of the enzyme. Substrate binding
displaces the water distal ligand, which converts the enzyme from a low-spin (hexacoordinate) to
a high-spin state (pentacoordinate) as illustrated in Figure 9 [Sligar, 1976]. The change in spin
state lowers the redox potential of the heme, facilitating the initial reduction of the substrate-
bound cytochrome P450 by its redox partner (Step 2). Kominami et al. (1982) concluded from
their studies that the spin state does not control the electron transfer from the NADPH but did
conclude that the substrate is essential for the reduction of the P450 enzyme. One electron is
taken up by the iron which is therefore reduced to its ferrous form (Fe(II)) and remains in the
high-spin state. The loss of the sixth coordinate allows oxygen to bind to the cytochrome P450
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enzyme by heme ligation (Step 3). Once the dioxygen molecule has bound, the ferrous iron is
converted to a low-spin state. Electron transfer trom iron to oxygen occurs, resulting in the
formation of a ferric-superoxide species. The second electron is subsequently donated from the
cytochrome P450 redox partner, activating the oxygen, followed by an internal rearrangement of
the electrons restoring the iron to its ferric form (Step 4). The species formed, Fe3+-02-, is highly
reactive and may associate with 2 protons in the environment of the active site to form hydrogen
peroxide. Jn the monooxygenase reaction, two oxygen atoms are cleaved resulting in one oxygen
atom being incorporated into the substrate, the other into a molecule of water with the
subsequent release of water (Step 5). The oxygen insertion into the substrate is believed to
involve hydrogen abstraction from the substrate (Step 6) and then insertion of the resulting
hydroxyl into the substrate (Step 7) [Hall, 1986; Lewis, 2001].
Hexocoordinote, I.owspin Pentocoordinote, high spin
Figure 9. Illustration of the spin state of cytochrome P450 [reproduced from Hall, 19861.
Catalytic Properties of Cytochrome P450 enzymes
The cytochrome P450 active site contains a protoporphyrin IX moiety which is located in a
hydrophobic cleft of the apoprotein (Figure 10). The heme binds to a central metal ion which is
penta- or hexacoordinate. Four of the coordinates are occupied by the planar porphyrin ring,
bound by hydrophobic forces. The fifth ligand is the thiolate anion of a cystein residue while the
sixth ligand is either occupied by water or, when the iron is reduced, the sixth coordinate is the
site of dioxygen activation [Hall, 1986; Porter and Coon, 1991; Segall, 1997; White and Coon,
1980].
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Figure 10. Tbe active site of cytochrome CYPIOI io tbe absence of substrate. The water molecule represented by
a single oxygen atom forms tbe sixth axial ligand of the beme iron. The oxygen atoms are shown io red, nitrogen
in light blue, iron in dark blue, su]pJmr in yellow and carbon atoms are shown in grey as bonds [reproduced
from SegaU 1997]
Cytochrome P450 enzymes may be characterized using UV/visible spectrophotometry, identifying
different intermediates in the catalytic cycle. In the catalytic cycle of P450cam (CYPlOI), the
substrate free enzyme exhibits an absorption maximum at 417-420 nm which is associated with the
low spin state. The binding of the substrate brings about a change in the spin state to a high spin
state which exhibits an absorption maximum at 391 nm. Once reduced, this complex has an
absorption maximum at 40&nm and upon binding molecular oxygen the absorption maximum shifts
to 418 nm. The difference in the spectrum obtained is due to the energy level transitions in the heme
locus itself, which is influenced by the nature of the heme ligand, the environment theheme moiety
is in and the nature of the bound substrate or inhibitor [Kominami and Takemori. 1982; Lewis,
1996]. The low and high spin states are attributed to the characteristics of the central ferric iron
(Fe3+). In the low spin state (S = Yz) the five 3d electrons are maximally paired while during the high
spin state (S = 5/2) the five 3d electrons are maximally unpaired [Segall, 1997]. Substrates for the
P450 enzymes thus induce difference spectra when bound to the enzyme (Figure 11); however,
compounds that are not considered substrates for the enzymes are also capable of inducing
difference spectra. Three types of difference spectra have been characterized for Fe(lIl) P450,
depending on the type of ligand hound in the active site: type I and II and reverse type I (or
modified type II) [Lewis, 1996 & 2001].
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Figure 11. Type I (dashed line) and type II (solid line) difference spectra following the addition of a type I (5
mM hexobarbital) and Type II substrate (18 mM aniline) to cytochrome P450 enzymes in the liver
mierosomes (5 mg/ml protein) [reproduced from Omura and Sato, 19781.
A type I difference spectrum exhibits an absorption minimum at approximately 420 nm and an
absorption maximum between 385-390 nm. This reaction graphically interprets the interaction of
the P450 enzyme with its substrate. Since low-spin P450 enzymes absorb at 416-420 nm,
cytochromes P450 in high spin state absorb between 385-394 run, the type I substrate shifts the
Fe3+ spin equilibrium from a low-spin to a high-spin state (Figure 10) by displacement of the iron
from the plane of the ring toward the thiolate sulphur [Hall, 1987; Lewis, 1996 & 2001; Sligar,
1976]. Most cytochrome P450 substrates do induce the high-spin state of the enzyme and
therefore exhibit a type I binding spectrum. This change arises as a result of displacement of the
water molecule from the sixth position which causes the iron to shift out of the planar porphyrin
and toward the fifth or thiolate ligand. The binding of substrates that induce a type I spectrum is
illustrated in Figure 12. The percentages of the spin states can be calculated from the difference
spectra.
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Figure 12. An example of a substrate-bound system, camphor-bound CYPIO!. The binding of the substrate
displaces the water molecule. The oxygen atoms are shown in red, nitrogen in light blue, iron in dark blue,
sulphur in yellow and carbon atoms are shown in grey as bonds {reproduced from Segalll997J
A type II difference spectra is characterized by an absorption minimum between 390-405 nm and an
absorption maximum between 425 and 435 nm (Figure 11). As a result there is a shift to the longer
wavelengths, from a high-spin state to a low-spin state during which the iron atom shifts into the
plane of the heme which favours the low-spin state. The low spin form possesses a smaller ionic
radius compared to the high spin form. The substrates that fall in the type II category tend to be
cytochrome P450 inhibitors, inhibiting by binding directly to the Fe3+, replacing the water molecule
as illustrated in Figure 13. Most of these substrates contain atoms with non-bonded electrons, which
are able to bind to the heme locus.
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Figure 13. An example of an inhibitor-bound system, metyrapone-bound CYP10l. The inhibitor binds
directly to the heme FeJ+, replacing the water molecule as the sixth axial ligand. The oxygen atoms are shown
in red, nitrogen in light blue, iron in dark blue, sulphur in yellow and carbon atoms are shown in grey as
bonds [reproduced from Segall, 1997].
A reverse type 1difference spectrum earned this title because this spectrum is characteristically a
'mirror image' of the type I binding spectrum. It is also known as the modified type Il spectrum
as it closely resembles the type II binding spectrum. An absorption maximum between 409-445
nm and an absorption minimum between 365-410 nm is observed in this difference spectrum,
These substrates are not thought to ligate to the heme but rather displace the distal ligand and
bind elsewhere in the heme pocket [Lewis, 1996 & 200 1]. These reverse type I substrates usually
constitute relatively hydrophobic molecules, so that water is displaced by some form of
lipophyllic interaction within the heme environment during substrate binding.
The reduced form of cytochrome P450, iron (II) P450 also has its own characteristic UV
absorption spectrum, particularly in the presence of carbon monoxide. The wavelength of the
Soret absorption maximum is 450 nm, hence the name, cytochrome P450 [Omura and Sato, 1964
& 1978]. Changes of the Soret peak are dependent on the environment of the heme which means
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that the active site of a P450 enzyme will influence the electronic transition associated with the
band around 450 nm. This method is very effective in identifying and quantifying active P450
enzymes.
Most cytochromes P450 enzymes display simple Michaelis-Menton saturation kinetics and
competitive inhibition characteristics between substrates, but some isozymes display non-
hyperbolic kinetics which is carefully reviewed by Hlavica and Lewis (2001). An allosteric
effect may be responsible for the sigmiodal velocity versus substrate concentration curves. This
can occur when either, the second substrate molecule binds with greater affinity than the first, or
product formation is faster when both substrates are bound than when only one is bound to the
enzyme. Atkins et al. (2002) investigated the toxilogical advantage for non-hyperbolic kinetics in
the hepatic cytochrome P450 catalysis and they concluded that allostery can provide a
detoxification advantage at low to intermediate substrate concentrations and that at high
concentrations the allostery has neither a positive nor negative effect.
2.2.2 Mitochondrial cytochrome P450 enzymes
The cytochrome P450 enzymes, CYPII AI, CYPIIB I and CYPIIB2, are embedded in the inner
mitochondrial membrane of the adrenal cortex and use the mitochondrial electron transport
system, containing flavoprotein and ferredoxin (adrenodoxin reductase and adrenodoxin,
respectively). Some of the enzymes catalyze a single reaction while others catalyze a complex
series of reactions [Payne and Hales, 2004; Ruckpaul and Rein, 1990].
Plasma cholesterol is the initial substrate for steroid hormone biosynthesis. Cholesterol is also
synthesized from acetate in adrenal cells but is utilized to a lesser degree in steroid biosynthesis.
Plasma cholesterol circulates as lipoproteins and comprises 80 % of the circulating lipoproteins.
Cholesterol enters the adrenal cells by receptor mediated endocytosis as plasma cholesterylesters
bound to low density lipoproteins (LDL) and is stored as lipid droplets. ACTH stimulates adrenal
steroidogenesis since it upregulates LDL receptor expression in adrenocortical cells [Thomson,
2003]. Cholesterol bound to high density lipoproteins (HDL) destined for the liver is secreted
into the bile or converted into bile salts. The catalytic activity of cholesterol esterase is
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stimulated by ACTH, which liberates cholesterol from its esters to enter the mitochondria.
Cholesterol is subsequently delivered to the inner mitochondrial membrane by the function of
StAR, a short-lived mitochondrial import factor and not by means of passive diffusion. The
translation of StAR is induced by heightened levels of cAMP and PKA which occurs upon
ACTH receptor activation.
CYPII Al, which is associated with the inner mitochondrial membrane on the matrix side,
catalyses the first step in steroid hormone biosynthesis. The side chain cleavage of cholesterol to
form pregnenolone (PREG) requires three sequential hydroxylation reactions by CVP 11A and
requires 3 molecules of oxygen and 3 molecules ofNADPH for each reaction (Figure 14). The
first hydroxylation takes place at C22, followed by a C20 hydroxylation to produce 20a,22-
dihydroxycholesterol. The intermediate is then cleaved between C20 and C22 to produce the C2I
steroid, PREG and isocaproaldehyde. The CVP IIA I enzyme is expressed in all three adrenal
cortex zones, in the ovaries, testis and placenta of humans [Payne and Hales, 2004]. This enzyme
has also been detected in the central and peripheral nervous system of mice as well as in the rat
brain [Compagnone et al., 1995; King et al., 2004; MacKenzie et al., 2002].
~
IIADPH
IjO
CHOLESTEROL 22R-Hydroxycholesterol 20,22-0ihydloxycholesterl>j
Figure 14. Reactions catalyzed by CYPllA [reproduced from Payne and Hales, 2004]
The second group of mitochondrial cytochrome P450 enzymes includes, CVP 11Bland
CYP1IB2, which catalyze the final reactions in adrenal steroidogenesis. These enzymes are
expressed in the adrenal cortex and low levels of expression have been identified in areas of the
brain [MacKenzie et al., 2002; Yu et al., 2002; Mellon and Griffin, 2002]. CYPIIBI is mainly
expressed in the zona fasciculata and zona reticularis but has been observed in the mitochondrial
zona glomerulosa, whereas, CYPIIB2 is expressed exclusively in the zona glomerulosa of the
adrenal cortex [Payne and Hales, 2004]. The CYPIIBI enzyme catalyses l Iji-hydroxylation
(Figure 15A) of l l-deoxycorticosterone and l l-deoxycortisol (preferred substrate) to form
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corticosterone and cortisol, respectively [Payne and Hales, 2004; Ruckpaul and Rein, 1990].
CYl' 11B2 catalyses three sequential reactions converting l l-deoxycorticosterone to the
mineralocorticoid, aldosterone. The first reaction catalyzed is the 11~ hydroxylation of 11~-
deoxycorticosterone, followed by the hydroxylation of C 18 and finally an oxidation of the C 18
hydroxyl group to form aldosterone (Figure lSB). The intermediates are formed without being
released from the active site. Each of the reactions requires one molecule of oxygen as well as
one molecule ofNADPH. Unlike CYPIIB2, CYPIIBI is not capable of 18-hydroxylations and
therefore plays a more important role in the biosynthesis of the glucocorticoids namely,
corticosterone and cortisol [Kawamoto et al., 1992]. Cortisol secretion usually exceeds (lOO-
1000 fold) that of aldosterone. This phenomenon is not only due to the transcriptional regulation
of these enzymes but rather due to the differences in catalytic activities of these two enzymes
[Lisurek and Bernhardt, 2004].
~~'
11 -ueoxycorucosterone
021NAOPH
,'OH 0
.
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~
11-Deoxycortlcosterone
~NADPH
~
-t t-Deoxycortf sot
021 NADPH
~NADPH
Corticosterone 18-Hyd roxycortlcosterone
Figure 15. Reactions catalyzed by CYPllBl (A) and CYPllB2 (b) [reproduced from Payne and Hales, 2004).
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2.2.3 Microsomal cytochrome P450 enzymes
Both CYP 17 and CYP21 are present in the endoplasmic reticulum and catalyze the
hydroxylation at the C17 and C21 position in the adrenal microsomes. Electrons for both CYP 17
and CYP21 are supplied by NADPH-cytochrome P450 reductase.
PREG is hydroxylated by the CYPI7 enzyme to form 17a-hydroxypregnenolone (17-0H-
PREG). CYP17 subsequently catalyses the 17,20-lyase reaction of the intermediate to produce
DHEA (Figure 16). Similarly, progesterone (PROG) is also 17a-hydroxylated, to form 17a-
hydroxyprogesterone (l7-0H-PROG) which can be converted to androstenedione (A4) in some
species [Ruckpaul and Rein, 1990]. In humans PROG also converted to 16-0H-PROG. CYP17
is therefore capable of catalyzing both the 17a-hydroxylation and the17,20-lyase reaction of
PREG and PROG. CYP17 is at a branch point in the production of glucocorticoids and adrenal
androgens (DHEA and A4). In the production of glucocorticoids, the 17a-hydroxysteroid
intermediates are further hydroxylated by CYP21 (discussed below) whereas in the production of
adrenal androgens the 17a-hydroxysteroid intermediates are lysed by CYP 17 to form the adrenal
androgens [Ruckpaul and Rein, 1990]. The CYPI7 enzyme is expressed in the adrenal cortex
(only the zona fasciculata and zona reticularis), in the testis and in the ovaries [Machi no et al.,
1969]. Mutations in the CYP 17 gene lead to a reduction of both reactions catalyzed by CYP 17,
resulting in a reduced production of the androgens, and in the abnormal development of
secondary sex characteristics.
"" 6,:"
C2l
HO enolona
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17o-Hvdroxypregmerrolone 17a-Hydroxyprogesterone
C1906P021NAOPH ? + "H,CHO 1. 0 + C.. ,CHO
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Figure 16. Reactions catalyzed by CYP17 [reproduced from Payne and Hales, 2004J
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CYP17 is a complex enzyme with the hydroxylase activity of the enzyme being similar across
species but marked differences reported with regards to the lyase activity of the enzyme. In
addition, the preferred substrate for CVP 17 differs across species - human CVP 17 more readily
converts the (15 steroids while rodent CVP 17 prefers the (14 steroids as substrate [Brock and
Waterman, 1999; Nakaj in and Hall, 1981]. The hydroxylase and lyase activity is also tissue
specific. Brock and Waterman (1999) indicated that the presence of cytochrome b5 stimulates
lyase activity in bovine and human adrenals, while Swart et al. (2003) concluded that a lack of
lyase activity in the ovine adrenal is as a result of the absence or presence of a modulating
condition or substance (phosphorylation or membrane environment) other than cytochrome b5.
The second cytochrome P450 present in the endoplasmic reticulum of adrenocortical cells is
CYP21, which catalyses the 21-hydroxylation of PROG and 17-0H-PROG to DOC and
deoxycortisol, respectively (Figure 17). The CYP21 enzyme is expressed in all three zones of the
adrenal cortex [Payne and Hales, 2004] and CYP21 activity [Mellon and Miller, 1989] and
expression [Beyenburg et al., 2001] has also been demonstrated in the human brain.
c~ c~~~C#
Progesterone 17a-Hydroxyprogesterone
021 NADPH 021NADPH ' .."
~~OH
~~
11-Deoxycortlcosterone 11-Deoxycortlsol
Figure 17. Reactions catalyzed by CYP21 [reproduced from Payne and Hales, 2004J.
3~-Hydroxysteroid dehydrogenase (3~HSD) belongs to the short-chain alcohol dehydrogenase
family [Penning, 1997]. Two distinct isoforms of this enzyme have been identified in humans
namely, 3~HSD type J (expressed in the placenta, skin and breast tissue) and 3~HSD type II
(expressed in the adrenal gland, ovary and testis). This enzyme is responsible for the conversion
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of PREG to PROG, 17-0H-PREG to 17-0H-PROG and DHEA to A4 [Payne and Hales, 2004;
Ruckpaul and Rein, 1990]. The Michaelis-Menten constant (Km) of 3~HSD is lower for DHEA
than for 17-0H-PREG or PREG [Conley and Bird, 1997]. Two sequential reactions convert the
~5 -3~-hydroxysteroids to ~4-3-ketosteroids (Figure 18). The first step involves the 3~ hydroxl
group followed by the isomerization ~5 -3-ketosteroids to form the ~4-3-ketosteroids. The
dehydrogenation reaction requires NAD+ which, when reduced, activates the isomerization
reaction. The ~4-3-ketosteroids are formed without the release of an intermediate or coenzyme.
Pregnenolone preg n-5-ene-3, 20-<1ione Progesterone
Dehydroepiandrosterone 5-Androstene-3, 17-dlone Androstenedione
Figure 18. Reactions catalyzed by 313HSD1reproduced from Payne and Hales, 20041.
2.2.4 Inhibition of cytochrome P450 enzymes
The P450 enzymes may be inhibited by a variety of molecules in a variety of ways: heme
ligation, hemeadduct formation, competition inhibition, formation of a reactive intermediate or a
combination of the aforementioned [Halpert, 1995; Lewis 1996 & 2001]. In addition,
cytochrome P450 inhibitors may be selective in that they inhibit a single P450 enzyme while
others are non-selective and inhibit many P450 enzymes. Carbon monoxide, nitric oxide and
cyanide inhibit cytochrome P450 enzymes non-selectively and readily bind irreversibly to the
heme iron. Selective cytochrome P450 enzyme inhibitors usually inhibit by competitive
inhibition and are often type TIligands binding reversibly to the heme iron.
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Organic ligands such as quinoline, furan, benzimidazole, pyridine and triazole, contain sterically
unhindered nitrogen or oxygen atoms with free valence electrons which act as inhibitors by
binding reversibly to the heme iron [Testa and Jenner, 1981]. Some cytochrome P450 enzyme
inhibitors interact with the heme moiety of the enzyme as a result of an enzyme-mediated
activation - the metabolic intermediate formed by the enzyme complexes with the heme
[Murray and Reidy, 1990]. This type of inhibition is referred to as mechanism based inhibition.
A selective inhibitor for CYP21, 21,21-dichloroprogesterone, is an example of such a
mechanism-based inhibition.
Metal ions also act as cytochrome P450 inhibitors and appear to inhibit by competing with the
iron for the heme porphyrin. Competition would be greatest with metal ions that have the closest
ionic charge, ionic radius and redox potential to iron, of which manganese (Mn2+), nickel (Ni2+),
cobalt (C02+) and cadmium (Cd2+) are examples.
Various inhibitors of the cytochrome P450 enzymes are of pharmacological importance and are
used in treating diseases of the adrenal gland. Increased levels of cortisol and aldosterone
contribute to severe diseases such as Cushing's syndrome, metabolic syndrome, hypertension
and increased mortality in congestive heart failure [Bureik et al., 2004; Muller-Vieira et al.,
2005]. Metyrapone, a known inhibitor of CYP11Bl, which catalyses cortisol biosynthesis,
lowers cortisol levels and is most commonly used in the treatment of Cushing's syndrome
[Verhelst et al., 1991]. Aminoglutamide, a more toxic drug, is prescribed together with
metyrapone and inhibits earlier cytochrome P450 enzymes in the steroidogenic pathway, thus not
only inhibiting cortisol biosynthesis [Child et al., 1976]. Trilostane inhibits 3~HSD and is used
in patients with adrenal adenomas [Semple et al., 1983]. Trilostane inhibition is not used in
treatment of Cushing's syndrome because inhibition is overcome by the rise in ACTH.
Ketoconazole is widely used as an anti-fungal agent, which can cause abnormal liver function.
Ketoconazole also contains the potential to lower cortisol levels by blocking various
steroidogenic cytochrome P450 enzymes [Contreras et al., 1985; McCance et al., 1987].
Mitotane is an adrenolytic drug used in the management of adrenal carcinoma and is taken up by
both normal and malignant adrenal tissue [Nieman, 2002]. Thus, finding selective inhibitors for
the steroidogenic enzymes which catalyze the reactions involved in steroid biosynthesis,
Stellenbosch University http://scholar.sun.ac.za
37
lowering the levels of cortisol and aldosterone, would be useful for the treatment of diseases
associated with their chronic elevation.
2.3 Summary
Psychological stress results in the activation of the HPA-axis, leading to elevated levels of
plasma glucocorticoids. The stress-induced rise in glucocorticoid levels does not protect us from
the source of stress but rather from the body's reaction to stress, minimizing an overreaction that
might threaten homeostasis. The HPA-axis is a complex system that is intricately regulated by
neural and endocrine systems. Glucocorticoids, cortisol and corticosterone regulate the HPA-axis
by negative feedback. The negative feedback is assumed to be sufficiently delayed to allow the
appropriate defence mechanism to be activated. Plasma cortisol concentrations are regulated by
the concentrations of the plasma steroid binding proteins and their free versus bound ratios.
DHEA is also hyper secreted in chronic stress situations, antagonizing the effects of cortisol.
Cortisol biosynthesis and secretion into the systemic circulation is regulated by ACTH.
Regulation of on a transcriptional level is associated with effects relating to long term exposure
to stress while acute effects influence the secretion of the hormones. Cortisol is synthesized in
the adrenal gland from cholesterol by the cytochrome P450 enzymes. Chronic elevations of
ACTH increase the synthesis of the cytochrome P450 enzymes. The activity of the cytochrome
P450 enzymes is regulated by the availability of: cholesterol, the initial substrate for steroid
hormone biosynthesis; NADPH, as an electron source; and the reductases, for the transport of
electrons from NADPH to the P450 enzyme.
In chronic stress situations, the negative feedback regulation of the HPA-axis is overridden,
leading to permanently elevated levels of basal plasma cortisol concentrations. Prolonged
exposure to elevated concentrations of cortisol are associated with a number of ailments and in
general renders one more susceptible to disease [Chrousos 1999]. Adverse effects associated
with elevated cortisol levels may be alleviated by inhibition of the cytochrome P450 enzymes
responsible for cortisol biosynthesis. Although the P450 enzymes are highly specific for their
natural steroid substrates, inhibitors of the expressed P450 enzymes are usually not specific for
single P450 enzymes but have inhibitory activity on all the P450 enzymes of the steroidogenic
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pathway. Compounds similar in structure to the natural steroids may inhibit the catalytic activity
of cytochrome P450 enzymes binding in the heme pocket of the enzymes. In addition, the
cytochrome P450 enzymes can be inhibited by influencing other role players required for
enzymes catalysis, such as the phospholipid environment and electron transport systems.
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Chapter Three
Sutherlandia frutescens
Natural products represent an enormous reservoir of molecular diversity to drug discovery and
development. Approximately 50 % of drugs in clinical use comprise natural plant products and
their derivatives and higher plants represent no less than 25 % thereof [Van Wyk and Wink,
2004]. It took many centuries, through a process of trial and error, to develop the profound
knowledge of traditional medicine. Since the functions of the body are currently better
understood we are able to appreciate the potential of plants in treating complicated health
conditions by acting as multifunctional chemical entities. Although natural products are normally
taken in their crude form as teas (infusions), sophisticated phytomedicines have been
standardized and extracts of plants have been formulated and undergone rigorous testing. The
use of natural products and phytomedicines has become a more popular option than medicinal
products derived from synthetic chemicals. The emphasis at present is therefore to support
serious medical claims made by traditional medicines with clinical studies, establishing the
safety and efficacy of these practices.
South Africa boasts a rich plant and cultural diversity and a large number of plants are used for
medicinal purposes, one of which is Sutherlandia frutescens. It is estimated that there are
approximately 3000 South African plant species used for medicinal purposes [Light et al., 2005;
Van Wyk et al., 1997]. Since South Africa is a developing third world country, herbal medicines
form the backbone of rural healthcare, not only for economical reasons but also for cultural
reasons.
3.1 Botanical nomenclature, description and distribution
The Sutherlandia (L.) R.Br genus belongs to the Fabaceae family and is commonly known as
Cancer bush. The Fabaceae (pea & bean or pod-bearing family) is the second largest flowering
plant family which contains 600 genera and 12 000 species, distributed throughout the world.
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This family of plants is represented in Southern Africa by 134 genera and more than 1300
species. Sutherlandia comprises 6 taxa, all endemic to Southern Africa [Moshe et al., 1998] and
closely related to the Lessertia genus, sometimes considered a part thereof. Analysis of the gene
product of 32 enzyme coding loci, performed by Moshe et al (1998), revealed genetic variation
in 18 loci. Large overlaps were found in cluster analysis of genetic distance data indicating that
members of the Sutherlandia taxa are not easily genetically distinguishable. The genus
Sutherlandia was named after James Sutherland, the first Superintendent of the Edinburgh
Botanic Garden and the species frutescens means bushy in Latin. Common names for S.
frutescens are balloon pea, Umnwele (Xhosa and Zulu), kankerbos (Afrikaans), Insiswa,
Mukakana and Phetola. S. frutescens is often confused with its other closely related species,
Sutherlandia montana (mountain cancer bush), Sutherlandia microphylla and Sutherlandia
tomentosa. Lack of agreement between morphological and allozyme patterns within the genus as
well as low allozyme differentiation between populations and taxa may be a result of the
breeding mechanism [Moshe et al., 1998].
The malachite sunbird (Nectarinia famosa) pollinates the Sutherlandia taxa [Arroyo, 1981]. The
birds' ability to travel long distances makes it possible to transfer genetic material from
geographically isolated populations and consequently result in the recombination of alleles
between taxa. It has been suggested that the flowers may become c1eistogamous, enabling self-
pollination, resulting in a population becoming larger till pollinators are attracted [Moshe et al.,
] 998]. The high level of integration and recombination among the taxa does not fully support the
idea that the genus comprises 6 taxa. Furthermore, Moshe et al (1998) found it impossible to
differentiate between the taxa due to a lack in unique alleles. The significant characteristics
distinguishing the different taxa are habitat, orientation of fruit stipe, shape and pubescence of
the leaflets and the shape of the pods [Moshe et al., 1998]. Results obtained from a combination
of characteristics have, to date, not conclusively established the genus to which the shrub
belongs. Since it was found that the Sutherlandia taxa have very low genetic differentiation, the
South African genus may belong to one variable taxon, S. frutescens.
S. frutescens is a small attractive shrub and the lively colours of the shrub appeal to many. The
Sutherlandia taxa were in fact grown as ornamentals as early as 1683 in England and some
species are still popular garden varieties. The perennial, soft wooded shrub grows up to 2 meters
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in height. The leaves which are bitter in taste, are divided into smaller leaflets (4-10 mm) which
may be slightly to densely hairy giving the plant a silvery appearance [Van Wyk et al., 1997].
The shrub produces large (35 mm long), bright red flowers in spring to mid-summer (September-
December), followed by almost transparent bladder-like papery pods. The six species identified
are, however, hard to distinguish from each other.
Sutherlandia genus is distributed mainly in the arid regions of southern Africa, in Western Cape
and Karoo regions of South Africa as illustrated in Figure 1 [Fernandes et al., 2004; Van Wyk et
al., 2000]. The S. frutescens species is restricted to southern Africa and occurs in Namibia,
Botswana, and South Africa [Van Wyk et al., 1997]. S. frutescens populations usually comprise
a relatively small number of plants in an area of less than 500m2. These populations are widely
distributed and show remarkable regional variation. Raw materials for medicinal purposes were
usually wild harvested with selected chemotypes cultivated on a commercial scale. S. frutescens
is a hardy, fast growing plant which tolerates all soil types. Although S. frutescens occurs in
summer and winter rainfall regions, it thrives in full sun and is drought resistant. Seeds are
usually sown in autumn or spring in well drained soil. Germination usually occurs 2-3 weeks
after planting.
Figure 1. Distribution of S.frutescens in South Africa [Van Wyk et al., 1997J
3.2. Phytomedicines and traditional remedies
Phytomedicines are derived from medicinal plants and affect varIOUS biochemical
pathways either directly or indirectly to restore physiological equilibrium and balance. The
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bioactive compounds of this category of medicinal plant products have in most cases been
identified and quantified, allowing the marketing of a standardised final product. A few
examples of natural medicines include St John's wort (Hypericum perforatum), Echinacea
(Echinacea purpurea) and Ginkgo biloba. Traditional remedies on the other hand lack
standardised levels of bioactive compounds. However, the popularity of herbs and botanicals is
supported by the demand, as is reflected in the United States consumer market which comprises
half the total market for supplements. These supplements include homeopathic products,
vitamins, minerals and sport supplements [Van Wyk and Wink, 2004; Eisenberg et al., 1998]. In
1998, the value of trade in ethnomedicinal plants in KwaZulu-Natal alone was estimated to be
worth R60 million [Mulholland and Drewes, 2004]. A survey performed by the World Health
Organization indicated that 70-80% of the world's population relies on non-conventional
medicine (mainly herbal sources) as their primary healthcare [Akereie, 1993]. It is thought that
orthodox medicines are considered to be an allopathic form of treatment while alternative
medicines, herbal or traditional remedies, involve a holistic approach for the body's self-
regeneration [Chan 2003].
African traditional medicines are considered to be the oldest and most diverse of all medical
systems but are, unfortunately, also the most poorly recorded [Van Wyk and Wink, 2004].
African herbal remedies stem from the Khoi-San and Nama people of Southern Africa who
themselves are considered the most ancient culture in Africa. In South Africa, traditional
medicine is more accessible than Western medicine for the majority of the population and it is
estimated that 60% of the population consult one of200, 000 traditional healers [Van Wyk et al.,
1997]. Medicinal plant tonics are used to maintain and support general and physical health in
healthy individuals while, during illness, they assist in restoring health by possibly stimulating
the immune function. Medicinal plant tonics enhance metabolism and improve digestion through
stimulation of the gall-bladder. Liver and kidney function is also stimulated to aid secretion and
excretion of waste products [Van Wyk et al., 1997; Van Wyk and Wink, 2004]. Traditional
healers in South Africa are most commonly known as, amongst others, 'inyanga' and 'isangoma'
which refers exclusively to herbalists and diviners respectively. This distinction, however, has
become blurred, with some healers practicing both arts. In South Africa, the claimed effects of
only a small number of approximately 3000 medicinal plants have been scientifically validated.
Although the change in the socio-political climate over the past 10 years has increased consumer
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awareness, data with regards to the safety, efficacy, and bioactivity of medicinal plants remains
limited. Funding supporting research of African traditional medicines stimulated ethnobotany
and ethnopharmacology research to shift towards the integration of traditional herbal medicine
into primary healthcare [Light et al., 2005].
Members of the Fabaceae family are associated with strong antibacterial activity (Erythrina
lysistemon Hutch), antifungal activity (Glycyrrhiza glabra L.), antimalarial activity (Caesalpinia
volkensii Harms) and antioxidant potential [Van Wyk and Wink, 2004]. S. frutescens is one of
the few South African medicinal plants marketed internationally and is currently considered the
most profound adaptogenic tonic in South Africa.
3.2.1 Preparation and dosage
Traditional healers take many factors into account when harvesting medicinal plants - the
regional climatic conditions, aspect of mountain slope, type and moistness of the soil and time of
day. These factors have been identified by healers to influence the potency of medicinal plants.
Various processing procedures may also affect the chemistry of the medicinal plants. Some
plants are used in the fresh state while many are dried in the sun or shade or may be cut into
slices to dry. Plant material may be stored as is or reduced to a fine powder and stored in paper
bags, newspapers, glass jars or tin cans [Van Wyk et al., 1997].
African, Western, as well as Chinese herbal remedies are usually specific mixtures or formulas
of up to 20 different types of herbs. The recipes of these traditional medicines are contained in
ancient compendia. It is important to understand the nature of the active compound(s) since the
use of alcoholic extracts (tinctures) for example, may result in ineffective treatment or harmful
side effects compared to the use of traditional water extracts. Not only is the manner of
administration important for the effectiveness of the compound(s) but so is the correct dosage
[Van Wyk and Wink, 2004]. Herbal drugs or botanicals usually have a wide therapeutic window
in that the effective dose differs substantially from the toxic dose. However, as with every rule
there is always the exception and qualified individuals should therefore be responsible for
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prescribing the remedies. Pure compounds on the other hand have a much smaller window and
the desirable dose is easily exceeded to reach toxic levels [Van Wyk and Wink, 2004].
The biologically active compounds of plants are often found in different parts of the plant, while
one plant part may be toxic, another may be harmless. In phytotherapy it is either the whole plant
or a specified part of the plant that is used. Bark is used frequently in phytotherapy since it often
contains high concentrations of active components, for example, quinine bark (Cichona species:
Chinae cortex) and willow bark (Salix species: Salicis cortex) [Van Wyk and Wink, 2004]. Many
other specific parts of plants containing bioactive compounds are used in herbal remedies - the
flower, wood, leaf, seed, fruit, resin, gum, bulb, tuber or root. There are also a number of forms
in which herbal medicines can be administered - teas, decoctions, macerations, infusions,
juices, syrups, oils, pills, lozenges, capsules, tablets and even spirits or essences. The polarity,
stability and other chemical characteristics of the active ingredient(s) in medicinal remedies and
the ease with which the active ingredient(s) enter the human target cells, determines the route of
administration. Different herbal medicines have been identified to be active only when
administered orally, nasally, topically, rectally, by smoking or steaming, bathing and
subcutaneous or intramuscular injection [Van Wyk and Wink, 2004]. In addition, more volatile
compounds may be effective when inhaled but inactive when taken orally.
The leaves of S. frutescens are mainly used in traditional remedies but all above ground parts of
the plant are usually included [Van Wyk et al., 1997]. Strong decoctions or alcoholic tinctures
are administered and are sometimes mixed with other ingredients. Decoction refers to a
preparation made by adding cold water to the required amount of herb which is boiled for 5 to 10
min and strained. An alcoholic tincture contains 70-30 % alcohol in which the plant material is
boiled for a specific time and strained. These traditions stem from the Khoi and Nama people
who used decoctions externally to wash wounds and internally for fevers and other ailments
[Van Wyk et al., 1997]. Traditionally, 1-2 g of S. frutescens dry herb was administered as a tea
or decoction [Van Wyk and Wink, 2004]. The recommended dosage of S. frutescens for humans
is 9mg/kg body weight per day [Seier et aI., 2002]. This recommended dosage is based on the
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tablets of the dry herb currently on the market', which recommend two tablets a day each
containing 300 mg of dried plant material.
3.2.2 Medicinal potential of traditional remedies - efficacy and safety issues
Efficacy of a traditional medicine is evident at different levels with information being passed
down from generation to generation, as well as from practitioners making clinical observations.
Pharmacological studies further demonstrate activity in vitro, in vivo, ex vivo and observational
studies, which include large groups of people, may provide information showing statistically
significant benefits. Clinical studies would, however, provide the most significant and
convincing scientific method for proving safety and efficacy of traditional medicines [Van Wyk
and Wink, 2004]. Clinical trials involve four phases which are usually monitored on a yearly
basis. After preclinical trials, 30-40 healthy patients are examined to determine the best and
safest dose as well as the best form of administration. The next phase requires the participation
of 100-1000+ people to determine if the drug is effective and for further evaluation of its safety.
The final phase also involves a large group of people to test the drug against a current standard
treatment. A successful trial would show a statistically significant difference between the treated
and control groups.
Standardized extracts of traditional medicines are established by testing the biological activity of
different extracts of the medicinal plant. After safety and toxicity studies of the standardized
extract have been completed, industrial production can begin. Clinical tests are subsequently
carried out which may result in the extracts approval for drug development. The approval of
specific chemical compounds isolated from medicinal plants is, however, more complex and
time consuming. The processes required for the approval of standardized extracts and pure active
compounds is summarized in Figure 2. Specific chemical compounds may only be approved for
industrial production after structure-activity relationship studies (SARs), toxicity and safety
studies, clinical tests and an appropriate pharmaceutical formulation has been established [Pieters
1 www.bioharmony.co.za
www.health-connection.co.za
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and Vlietinck, 2005]. Some of the general requirements for a bioassay used in the screening of
plant extracts include: validity, lack of ambiguity, accuracy, reproducibility, simplicity and
economic viability. It is therefore evident that the investigation of medicinal plants is a
multidisciplinary process. Since the approval of standardized extracts of medicinal plants is more
rapid and economically viable, it is the starting point for a successful pharmaceutical industry in
developing countries.
I FLOW CHART FOR THE STUDY OF PLANTS USED IN TRADITIONAL MEDICINE
SAR-STUDIES
INDUSTRIAL PRODUCTION OF
STANDARDIZED EXTRACT(S)
PHARMACEUTICAL FORMULATION(S)
"------1 APPROVAL AS DRUGS
Figure 2. Processes for studying efficacy of standardized medicinal plant extracts as well as active compounds
for their approval as drugs [Pieters and Vlietinck, 2005]. SAR-studies refer to the structure-activity
relationship studies.
Verpoorte et al (2005) suggest that efficacy studies of traditional medicine requires a holistic
approach which includes mental, social and physiological factors as apposed to the single
compound single target approach. The holistic or in vivo approach for testing medicinal plants
can be achieved by either clinical trials or animal studies. Quantitative analyses of all metabolites
in the test organism may determine the holistic effects of herbal remedies, an ultimate though
somewhat ambitious goal [Patwardhan, 2005; Verpoorte et al., 2005]. Methods most commonly
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used to identify and quantify the various metabolites include chromatography based methods
(HPLC, GC), molecular weight based methods (mass spectrometry) and physical characteristic
based methods (NMR spectrometry) [Verpoorte et al., 2005]. These analytical procedures are not
only important methods in analyzing changes in metabolites in the test organism but also in
analyzing the metabolites present in the plant itself. It is important that active compounds are
isolated and identified, not necessarily for drug development but to understand the efficacy of
medicinal plants in human health care and determine the bioavailability of the bioactive
compounds in a biological system.
Poisoning from traditional medicines can be a consequence of misidentification, incorrect
administration, dosage or preparation of the plant material, due mostly to self-administration
[Barnes and Prasain, 2005; Fennell et al., 2005]. Johannesburg's forensic database for 1991 to
1995 revealed that 43 % of the poisoning cases were attributed to traditional plant medicines
[Stewart and Steenkamp, 1999]. When compared to accidental deaths from inappropriate use of
conventional medicines, toxicity of traditional medicines is rare. Herbal remedies may be
contaminated with excessive or banned pesticides, microbial contaminants, heavy metals,
chemical toxins or even the presence of orthodox or conventional drugs [Chan, 2003; De Smet,
2002; Marcus and GrolIman, 2002]. The source of these contaminants can be associated with the
cultivation, drying, storage or processing of the plant material. Furthermore, the quality of herbal
medicines may be compromised by a plant's popularity or scarcity, resulting in the trade of poor
quality plants or in the deliberate substitution with other plant material for economical reasons.
The substitution of other or poor quality plants may, however, be an error in incorrect
identification. Incorrect possessing procedures may result in toxicity as the processing and
preserving procedures normally reduce toxic components in crude extracts and may also enhance
the activity of the active compounds. It is advisable that the bioactive plant extracts be tested for
toxic effects since the difference between the levels of toxicity toward the parasite versus toxicity
towards the host may be minimal. Analytical methodologies to assess contaminants present in
herbal remedies are carefully assessed in the review article by Chan (2003).
Misidentification of medicinal herbs may inevitably result in misadministration of the herbs. The
identification of the different medicinal plants and their extracts may be addressed by using
chromatographic techniques. Springfield et al (2005) investigated HPLC fingerprinting in the
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identification and quality assessment of South African herbal medicines. In cases where
botanical identification was impossible, HPLC with diode array detection (DAD) was used to
provide a qualitative profile or chemical fingerprint of the compounds present in the crude drugs
or their extracts. HPLC-DAD is a sensitive, rapid and economical technique which can be
implemented in developing countries with relative ease to promote the rational use of medicinal
plants. The qualitative identification of chemical compounds by HPLC is achieved by
comparison of retention data. Springfield et al (2005) compared chromatograms of 3 different
collections of Chironia baccifera which were qualitatively sufficiently similar. Since plant
material contains highly variable concentrations of active compounds these differences in
concentrations can be clearly observed on the chromatograms. HPLC methods of identification
may be used to regulate concentrations of active compounds in medicinal plants, once a
therapeutic concentration range has been established [Van Wyk and Wink, 2004]. Interestingly,
the different analytical procedures used to identify and quantify some of the compounds present
in the herbal remedies have identified surprisingly few compounds for conventional drug use.
This suggests synergistic actions of other compounds in the herbal remedy which are either
chemically unknown or have not been isolated and identified in the herbal mixture.
The absence of regulation together with the increased popularity of medicinal plants in South
Africa has brought the danger of misadministration and possible genotoxic effects associated
with prolonged use to the fore. Without regulation, contaminants may be present and remain
unidentified in herbal remedies possibly leading to adverse side effects [Chan, 2003; De Smet,
2002; Marcus and GrolIman, 2002]. The presence of contaminants in medicinal remedies is
being acknowledged since 50 South African plants were recently screened for genotoxic or
mutagenic effects [Verschaeve et al., 2004]. Screening has, however, identified compounds with
the following properties antibacterial, antifungal, anthelmintic, anti-amoebic,
antischistosomal, antimalarial, anti-inflammatory and antioxidant potential, neurotropic and
psychotropic activity [Fennel et al., 2004]. Thus, the investigation of traditional medicines is not
only invaluable in ensuring the safety of medicinal plants for their continued use but also for the
discovery of novel drugs. The administration of medicinal plants should be controlled by
standard operating or regulatory procedures to reduce risks and to support the belief that
traditional medicines may be safer than synthetic medicines. The regulation of traditional
medicines should not only occur at the level of product development but practitioners should be
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registered and strict standards put into place to avoid prescriptions of potentially lethal doses [De
Smet, 2002; Marcus and GrolIman, 2002]. Furthermore, regulation and quality control would
ensure the correct identification of the medicinal plants, therapeutic concentrations of active
ingredient, purity and hygiene, as well as skilled practitioners. The conservation status of
medicinal plant resources requires attention since over-collecting may lead to the extinction of
medicinal plant species. These aspects together with the effect of cultivation and post-harvest
storage on the biological activity of medicinal plants are not addressed fully as they do not fall
within the scope of this study [Light et al., 2005; Fennel et al., 2004].
3.3. Bioactive compounds
Bioactive compounds identified in plants are usually secondary metabolites or natural products
which are low molecular weight compounds that do not playa role in primary plant metabolism.
Although the plant often uses secondary metabolites as a defence mechanism or to attract
pollinators, these compounds are not essential for the survival of the plant. There are 3 major
groups of secondary metabolites which include the nitrogen-containing substances (includes the
non-protein amino acids), the terpenes (includes saponins) and the phenolics.
These secondary plant metabolites must ultimately interact with a molecular target in the human
body for the compounds to be therapeutically effective. Since extracts of medicinal plants
contain a variety of chemical entities, the plant is able to affect more than one molecular target,
which increases the chances of efficacy, restoring health or relieving symptoms of physiological
disturbances. Allopathic or conventional medicines, however, use a single compound to treat
disorders. Some active compounds have been isolated from medicinal plants and are used in
treatment as a single chemical entity - atrophine, reserpine morphine, quinidine, digoxin or
vinblastine [Van Wyk and Wink, 2004]. In contrast, a single medicinal plant may contain many
active compounds which would include a bitter substance for stimulation of digestion, phenolic
compounds which act as anti-oxidants and venotonics, diuretic substances to enhance the
elimination of waste products and toxins, anti-bacterial and antifungal tannins, anti-inflammatory
compounds as well as alkaloids to enhance moods to give a sense of well being.
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Although no alkaloids have been identified in S. frutescens, a small number of saponins and
other bioactive compounds have been characterized. One of these compounds L-canavanine, a
non-protein-a-amino acid, acts as an arginine mimic to reduce the uptake of essential amino
acids from the intestine thus disturbing protein biosynthesis. L-canavanine has also been
documented to exhibit anticancer and antiviral activity, as well as the ability to inhibit nitric
oxide synthase [Riganti et al., 2003; ABO EL-Gawad and Khalifa, 2001]. There is
approximately 30-40 mg of L-canavanine per dry gram of the S. frutescens leaf [Gericke et al.,
2001]. Tablets of Sutherlandia from Phyto Nova, analysed by Tai et al (2004), contained 3 mg of
canavanine per gram of tablet [Tai et al., 2004]. S. frutescens is also rich in gamma-aminobutyric
acid (GABA) (14 mg per gram dry leaf, 0.4 mg/g Phyto Nova tablet). GABA is an inhibitory
neurotransmitter that could account for the therapeutic use of the S. frutescens and S. microphylla
for anxiety and stress symptoms [Van Wyk et al., 2000]. The presence of these compounds in
extracts of Sutherlandia tablets, shown in Figure 3, were demonstrated by Tai et al. (2004). The
leaves also contain pinitol [Van Wyk et al., 1997 Van Wyk and Wink, 2004] which is a known
antidiabetic agent and has potential in treating muscle wasting in cancer and AIDS patients [Van
Wyk and Wink, 2004]. The structures of these compounds are illustrated in Figure 4.
Saponins are an important group of secondary plant metabolites which include triterpenoids,
glycosylated triterpenoids, glycosylated steroids and steroidal alcohols. [Haralampidis et al.,
2002]. The triterpenoids, present in many plant extracts including S. frutescens, have been
associated with bitter tonic effects, corticomimetic activity, anti-inflammatory, anti-ulcer,
antinociceptive and anti-tumoral properties [Inoue et al., 1990; Navarette et al., 2002; Fernandes
et al., 2003; Haridas et al., 2004]. The corticomimetic activity may be attributed to the structural
similarity to the endogenous hormones (glucocorticoids), which would account for the anti-
inflammatory effects of S. frutescens treatment. The triterpenoid present in S. frutescens is a
triterpenoid glucoside known as Sul. Tn addition, some flavonoid compounds have been
identified in the leaves of S. frutescens. In general, flavonoids have been associated with
scavenging of free radicals, anti-inflammatory activity and the suppression of nitric oxide
production [Saija et al., 1995; Solimon and Mazzio, 1998; Fushiya et al., 1999; ABO EL-Gawad
and Khalifa, 2001]. The structure of a flavonoid and triterpenoid are illustrated in Figure 5 to
demonstrate their structural similarity to the steroid hormones.
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Figure 3. LC/MS APCl chromatogram of amino acids and active compounds present in S. Frutescens
PhytoNova tablets extracts. The confirmation of pinitol was done using negative ion electrospray LC/MS [Tai
et (IL., 20041.
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Figure 5. The typical structure of a flavonoid, quercetin, found in apples, onions and teas IABD EL-Gawad
and Khalifa, 20011 and a triterpenoid saponin isolated from the fruits of Ternstroemia japonica [Shin et (II.,
20031
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3.4. Pharmacological effects of S. frutescens.
While herbal remedies are preferred for the treatment of chronic self-terminating conditions,
conventional medicine is used to treat acute or serious illnesses. As previously mentioned, S.
frutescens is a bitter tonic which has been used to treat stomach problems and improve quality of
life [Van Wyk 2004]. Traditionally, S. frutescens has also been used to treat colds, influenza,
chicken-pox, diabetes, varicose veins, piles, inflammation, liver problems, backache,
rheumatism, stress and anxiety [Van Wyk et al., 1997; Van Wyk and Wink, 2004; Neuwinger,
2000]. Furthermore, the plant has been used in the prevention and treatment of cancer, hence its
common name, Cancer bush [Moshe et al., 1998]. Cancer patients as well as AIDS and TB
patients tend to lose weight and 'waste' away. Anecdotal reports suggests that S. frutescens
dramatically improves the appetite and wasted patients gain weight and have increased energy
levels which enhance their sense of well-being [Morris, 2002]. In addition, the extracts have
been successfully used topically in the treatment of burns, wounds, inflammation and other skin
conditions [Van Wyk et al., 1997]. Traditionally no distinction is made between the use of S.
frutescens and S. microphylla for medicinal purposes [Van Wyk et al., 2000]. Although very
little scientific evidence is available on the medicinal properties of S. frutescens, tablets pressed
from the whole dried plant material have been manufactured and are marketed by Phyto Nova,
Cape Town, as a direct result of the many positive anecdotal reports. However, in the past two
years there has been an increasing interest in the use of S. frutescens as a medicinal remedy, most
specifically in the treatment of cancer and AIDS. Many research groups are currently
investigating the bioactivity of S. frutescens to determine the mechanism of action by which the
therapeutic effects are exerted and thus establishing a scientific basis for these effects. A
toxicology study has been carried out in vervet monkeys and showed that administration of S.
frutescens at nine times the recommended dose, 381 mg/kg body weight, had no toxic or side
effects, with regard to the haematological and biochemical parameters measured [Seier et al.,
2002].
Anti-inflammatory properties of medicinal plants can be partly attributed, to their anti-oxidant
potential. Hydrogen peroxide and superoxide radicals are phagocyte derived reactive oxygen
species (ROS) that are responsible for the pathogenesis of various inflammatory conditions. A
study by Fernandes et al. (2004) tested the effect of a hot water extract of S. frutescens on
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luminol and lucigenin enhanced chemiluminescence by L-formyl-Lmethionyl-L-Ieucyl-L-
phenylalanine (FMLP)-stimulated neutrophils and investigated the superoxide and hydrogen
peroxide scavenging properties in cell free systems. Results indicated that S. frutescens had
potent antioxidant potential by decreasing superoxide and hydrogen peroxide induced
chemiluminescence at concentrations as low as 10 ug/ml and 0.62 ug/ml, respectively. In
addition, they found that the extract had no adverse side effects on cell viability at concentrations
as high as 40 ug/ml, Since S. frutescens possesses significant ROS scavenging properties in cell
free and in stimulated neutrophil systems, the plant may therefore be an effective
immunomodulator in the treatment of diseases associated with an overproduction of ROS by
human phagocytes. The anti-oxidant activity may be attributed to the phenolic compounds
present in the extract, such as tannins and flavonoids but further analyses are required to identify
the relevant bioactive compound(s) [Fernandes et al., 2004]. In contrast to the findings of
Fernandes et al. (2004), Tai et al. (2004) analysed the antioxidant potential of ethanolic extracts
on nitric oxide production and reported no significant inhibition.
Although there is progress in the development of anticancer therapies, the incidence of cancer is
still on the rise worldwide. Chemoprevention is an approach widely used in cancer treatment and
refers to the use of a non-toxic substance either of natural or of synthetic origin, to block, reverse
or retard the process of carcinogenesis. Investigations into the chemopreventive properties of S.
frutescens were carried out by Kundu et al. (2004) who investigated the influence of methanolic
extracts of dried leaves of S. frutescens on the activity of cyclooxygenase (COX) 2. COX 2
catalyses prostaglandin biosynthesis and is induced by 12-0-tetradecanoylphorbol-13-acetate
(TPA). They reported that the topical application of a methanolic extract of S. frutescens (100-
200 ug) significantly decreased the TPA- induced COX-2 expression (26 and 48 % inhibition at
doses of 100 and 200 ug respectively) in mouse skin. Evidence suggests that the targeted
inhibition of inappropriately elevated expression or activity of COX 2 is desirable not only for
alleviating inflammation, observed in numerous malignancies, but also for preventing cancer
[Surh et al., 2001]. In determining possible mechanisms for the observed inhibition, they also
found that S. frutescens was capable of inhibiting transcription factors such as the activator
protein-l (AP-I) and the cyclic AMP response element binding (CREB) protein. In addition,
they observed inhibition of the catalytic activity, but not the phosphorylation, of extracellular
signal-regulated protein kinase (ERK), an upstream mitogen-activated protein kinase (MAPK).
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Although the inhibition is observed it is uncertain which active compounds are contributing
toward the inhibitory effect. It is possible that L-canavanine may be responsible for the benefits
reported by cancer patients since the compound exhibits anti-tumourigenic properties [Yang et
al., 2002; Van Wyk et al., ]997]. Furthermore, Tai et al. (2004) demonstrated antiproliferative
effects of an ethanolic extract of S. frutescens in various cancer cell lines. The antiproliferative
activity differed for each cell line and flow cytometry analysis indicated that the cell lines were
arrested at different phases of the cell cycle, suggesting more than one active compound. L-
canavanine, at high doses, was found to block all DNA synthesis, providing support for its role
in contributing to the anticancer properties of S. frutescens, but the concentrations of L-
canavanine used to achieve this result are much higher than concentrations present in the plant
extract [Tai et al., 2004]. More recently Chinkwo (2005) studied the anti-cancer effects of S.
frutescens by determining whether extracts were capable of inducing apoptosis in cultured
carcinoma cells. Apoptosis is programmed cell death, which if manipulated, can be used as yet
another therapeutic approach to cancer therapy. Apoptotic cell death is a physiological
mechanism that eliminates unwanted cells by triggering the cell's intrinsic suicide programme.
Apoptosis is characterized by morphological changes such as membrane blebbing, cell
shrinkage, protein fragmentation, chromatin condensation and DNA degradation, followed by
the engulfment of the resulting cell debris by the neighbouring cells [Christop, 2003]. Chinkwo
(2005) used several apoptotic tests to validate these properties of S. frutescens in vitro. The
results showed that S. frutescens exhibited apoptotic activity in three different cell lines by
displaying morphological disintegration and other changes in the cellular membrane viz. the flip-
flop translocation of membrane phospholipids indicative of apoptosis. The plant material
investigated was collected from three different regions (Kirstenbosch, Bloemfontein and the Free
state) and interestingly, all had different apoptotic activity, with the extracts from the Western
Cape plant specimens showing the greatest apoptotic activity. This observation emphasized the
importance of soil composition and other environmental factors on plant metabolites. Although
the mechanism of apoptosis is not fully understood, Chinkwo (2005) proposed that S. frutescens
activates the central death caspase 3 that is regulated by the apoptosome complex.
With over 40 million people worldwide infected with HIV, the World Health Organization has
embarked on a plan to have 3 million people taking antiretroviral therapy by 2005 [Duval, 2001;
Morris, 2001; Morris, 2002]. In response, the South African Department of Health has accredited
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27 facilities to provide AIDS care, including nutritional and micronutrient supplementation as
well as complementary and traditional medicines to delay the progression of the disease.
Products from medicinal plants have been reported to inhibit nearly all the stages of the viral life
cycle of HIV in vitro - sulphated polysaccharides (inhibit viral attachment) and calanolode A
(inhibits HIV reverse transcriptase) and other compounds with unknown modes of action [Yang
et al., 2001]. Anecdotal reports from doctors and health care workers suggest that S. frutescens
treatment in HIV -infected individuals results in weight gain, improved CD4 counts, decreased
viral loads, improved appetites and general mood improvements [Chaffey and Stokes, 2002].
The nutritional status of the HIV-infected individual can seriously influence the efficacy of anti-
retroviral and S. frutescens treatments" For example, S. frutescens contains L-canavanine which
is an arginine mimic which could enfold into the individuals proteins causing the immune system
to turn on itself, leading to serious diseased states. Thus a balanced diet, providing adequate
concentrations of arginine to out compete L-canavanine, is required to eliminate the toxicity of
L-canavanine. Anecdotal evidence suggesting S. frutescens may have antiviral properties
prompted Harnett et al. (2005) to investigate the possible inhibitory effects of extracts on HIV.
The inhibition of the glycohydrolase enzyme was investigated since the inhibition of this enzyme
was found to decrease the infectivity of the HIV virion [Collins et al., 1997; Harnett et al., 2005].
Results indicated that S. frutescens extracts contain inhibitory compounds active against HIV
target enzymes which include the glycohydrolase enzyme and HIV reverse transcriptase
(inhibition >50%), showing a potential mechanistic action of the plant in aiding HIV-positive
patients [Harnett et al., 2005]. Interestingly, inhibition of the reverse transcription assay was
reduced in the presence of BSA, suggesting that tannins may be responsible for the observed
effects. However, S. frutescens extracts still retained ~30% inhibition after the addition of BSA,
showing thus that the anti-HIVeffects observed may be attributed to other compounds.
Many antiretroviral medications, which are predominantly metabolized through the cytochrome
P450 3A4 (CYP3A4) oxidative metabolic pathway, are HIV protease inhibitors and non-
nucleoside reverse transcriptase inhibitors. HIV protease inhibitors are also substrates for drug
transporters like P-glycoprotein. The potential of S. frutescens to cause drug interactions with
anti-retroviral metabolizing mechanisms was investigated in vitro, testing the inhibitory effects
of the herb on CYP3A4 activity and P-glycoprotein expression. S. frutescens showed inhibition
2 www.gaiaresearch.co.za/Sutherlandia
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of both and in so doing highlighted the importance of in vivo investigations into the clinical
ramifications of the use of herbs or traditional medicine together with anti-retroviral therapy
[Mills et al., 2005a; Mills et al., 2005b].
As previously mentioned, the S. frutescens plant has also been used to treat stress. In fact, the
plant's Zulu name, unwele, meaning hair, refers to the fact that administration of the plant stops
people from pulling out their hair in distress. The success of traditional medicine in treating
mental illness is often attributed to the placebo effect rather than active compounds producing
the physiological response. However, active entities have been identified for psychological
treatment. The alkaloid compound isolated from Sceletium tortuosum (L.) N.E. Br.
(Mesembryanthemaeae) patented in 1997 (World Patent 9746234, 1997 Gericke and Van Wyk)
has been shown to playa role in the selective re-uptake of serotonin. It is administered in the
therapeutic management of depression [Fennell et al., 2004]. Chronic stress results in heightened
activation of the HPA-axis, resulting in chronically elevated cortisol levels which are associated
with a number of maladies as discussed in the previous chapter. Both cancer and HIV/AIDS are
also associated with an increased response to chronic stress. In a rat model of chronic
immobilization stress, Smith and Myburgh (2004) studied the effect of S. frutescens treatment on
selected serum hormone and cytokine levels. S. frutescens treated rats had decreased
corticosterone levels in response to chronic intermittent stress when compared to the control. It is
thought that the decrease in glucocorticoid levels may be responsible for the reported
improvement of quality of life and the decrease in muscle wasting of cancer and HIV/AIDS
patients. Possible target tissues for the anti-stress function of S. frutescens include the
hippocampus, where stress perception may be downregulated; the hypothalamus and pituitary,
where activation of the HPA-axis may be down regulated; or the adrenal gland where cortisol
biosynthesis may be downregulated.
3.5 Summary
S. frutescens, an attractive indigenous garden shrub, cultivated as early as the seventeen century,
has traditionally been used to treat a wide variety of ailments which presently also include HIV
and stress. The importance of phytomedicines, medicinal plant products and herbal remedies in
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the treatment of diseases is reflected in consumer market [Van Wyk and Wink, 2004; Eisenberg
et al., 1998]. In South Africa, traditional remedies are more accessible to the greater population
than conventional health care. The use of medicinal plants and herbal remedies in primary health
care should therefore be regulated and standardized, ensuring that this tradition remains safe and
economically viable. Imperative too to their prolonged therapeutic use is the need for scientific
validation - evidence supporting therapeutic claims of traditional remedies. Investigations into
the bioactivity of S. frutescens have shown anti-oxidant, anti-inflammatory, anti-stress,
antiproliferative and apoptotic activity, as well as conflicting reports in some instances
[Fernandes et al., 2004; Tai et al., 2004; Kundu et al., 2004; Chinkwo, 2005; Smith and
Myburgh, 2004). Recent analysis of S. frutescens extracts identified bioactive compounds which
include L-canavanine, pinitol, GABA, triterpenaids and flavonaids and these have been linked to
specific therapeutic applications [Riganti et al.,2003; ABD EL-Gawad and Khalifa, 200 I; Van
Wyk et al., 2000; Van Wyk and Wink, 2004; Inoue et al., 1990; Navarette et al., 2002;
Fernandes et al., 2003; Haridas et al., 2004; Saija et al., 1995; Soliman and Mazzio, 1998;
Fushiya et al., 1999). In HIV treatment, it was reported that although S. frutescens was capable
of decreasing the virulence of the HIV virion, it also interacted with CVP 3A4 and other
enzymes catalysing the metabolism of antiretroviral drugs [Mills et al., 2005a; Mills et al.,
2005b; Harnett et al., 2005). Research is therefore required to determine the physiological
consequences of treatment with S. frutescens when used in conjuction with antiretrovirals.
It is evident that therapeutic claims of S. frutescens are being validated by scientific evidence on
many fronts. In the next chapter evidence is presented supporting the potential stress relieving
properties of S. frutescens. The alleviation of negative effects associated with chronically
elevated cortisol plasma levels, a phenomenon experienced by both cancer and HIV IAIDS
patients as well as chronically stressed individuals, may be linked to the inhibitory effects of S.
frutescens on adrenal cytochrome P450 enzymes. Investigations were carried out to determine
the influence of S. frutescens extracts and of S. frutescens in tablet form on adrenal
steroidogenesis. These results together with investigations into the bioactivity of compounds
present in S. frutescens viz. pinitol, L-canavanine, GABA, triterpenaids and flavonoids, are
presented and discussed in chapter 4.
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Chapter Four
Inhibition of steroidogenic P450 enzymes by S. frutescens
4.1 Introduction
Sutherlandia frutescens has been used traditionally as a herbal remedy to treat the symptoms of
stress as well as many other ailments [Van Wyk and Wink, 2004]. The stress relieving properties
of the plant have been linked to its ability to influence plasma glucocorticoid concentrations
[Smith and Myburgh, 2004]. It was shown that S. frutescens extracts not only decreased
corticosterone levels in rats subjected to chronic intermittent immobilisation stress but also
increased basal corticosterone levels in non-stressed rats. S. frutescens may therefore exert its
stress relieving properties by influencing the HPA-axis acting as an adaptogen as well as by
down-regulating glucocorticoid production. As mentioned previously, the HPA-axis is
stimulated in response to stress which results in an increase in the concentration of circulating
glucocorticoids. The glucocorticoids released form part of a negative feedback mechanism to
regulate the activity of the HPA-axis and endocrine system. This regulatory feedback mechanism
is overridden in chronic psychological stress and diseases such as HIV/AIDS and cancer,
resulting in long-term exposure to elevated plasma glucocorticoid levels [Huizenga et al., 1998].
Negative side effects resulting from chronically elevated glucocorticoid levels [Chrousos, 1998]
may be alleviated by treatments which suppress glucocorticoid biosynthesis. Treatment would
therefore require the inhibition, or interference with the activity of the cytochrome P450 enzymes
which catalyse the biosynthesis of the glucocorticoids, cortisol and corticosterone. The aim was
therefore to determine if S. frutescens was able to influence the steroidogenic cytochrome P450
enzymes, thereby demonstrating a possible mechanism for reducing glucocorticoids levels.
The bioactivity of S. frutescens was assayed by investigating the effect of aqueous and methanol
plant extracts, single bioactive compounds and commercially available tablets on adrenal
cytochrome P450 enzymes. Although the therapeutic effects of a medicinal plant are thought to
be contributed to by compounds exerting synergistic effects, single compounds were also
investigated to determine if the effects could be attributed to any of the compounds tested.
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Compounds which were assayed for bioactivity include gamma-aminobutyric acid (GABA),
pinitol, L-canavanine, flavonoids and triterpenoids. GABA has been associated with mood
elevating properties [Van Wyk et al., 2000]; pinitol has anti-inflammatory properties [Van Wyk
and Wink, 2004] and L-canavanine has anti-viral and anti-cancer properties [ABD EL-Gawad
and Khalifa, 2002; Riganti et al., 2003].
Bioactivity assays were carried out based on the urnque spectroscopic properties of the
cytochrome P450 enzymes and on the conversion of specific substrates by these enzymes. Two
spectral assays, assay A and B were conducted. In assay A the ability of S. frutescens to induce
an inhibitor-induced difference spectrum was investigated. In assay B the effect of S. frutescens
on a substrate-induced difference spectrum was investigated. Since the ability of S. frutescens to
influence the conversion of cortisol precursors would serve as a measure of biological activity,
substrate conversion assays were carried out in the presence of S. frutescens. Two assays were
conducted in which the effect of S. .frutescens on the conversion of PREG and PROG was
determined. Assay A was conducted in ovine adrenocortical mierosomes and assay B in COS I
cells, a non-steroidogenic mammalian cell line. Expressing CYP 17 and CYP2l in COS 1 cells
allowed the determination of effects of S. frutescens on the catalytic activity of the individual
enzymes. As previously mentioned, CYPI7 is a complex enzyme, at a branch point in the
production of glucocorticoids and adrenal androgens. Compounds affecting the catalytic activity
of CYP 17 and CYP21 would not only influence the biosynthesis of cortisol but also the
precursor intermediates.
4.2 Materials and Methods
4.2.1 Materials
Sutherlandia specimens were collected from the Western Cape region of South Africa, and
identified as Sutherlandia frutescens subspecies microphylla', Plant material, leaves and stems,
were dried at ambient temperature in the shade for at least 5 days. Sutherlandia tablets were
purchased from Bioharmony (Phyto Nova) and Health Foods, South Africa. Sheep adrenals were
3 Kind gift from B-E van Wyk (Dept. Botany, University of Johannesburg, South Africa)
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collected from the Maitland Abattoir in the Western Cape. GABA, pinitol and L-canavanine
were purchased from Sigma Chemical Co (South Africa).
PEG 8000 was purchased from Sigma-Aldrich Chemie (Germany). PROG, PREG, DOC,
isocitrate and isocitrate dehydrogenase were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). NADH and NADPH were purchased from Boehringer Mannheim GmbH
(Germany). Radioactive tritiated steroids eH] PROG and rm PREG were purchased from
PerkinElmer Life Sciences (Boston, MA, USA). COS 1 cells were purchased from ATCC, USA.
Dulbecco's Modified Eagles Medium (DMEM) was purchased from Sigma-Aldrich and
Dulbecco's phosphate buffered saline was purchased from Gibco, Invitrogen Corp. (Canada).
Fetal calf serum and DMSO were purchased from Highveld Biological (South Africa).
Penicillin-streptomycin and Tripsin-EDT A were purchased from Invitrogen Corp. (Canada).
Spectra were recorded on a Varian Cary 219 spectrophotometer. Chromatography was performed
on a Waters (Milford, MA, USA) high performance liquid chromatograph coupled to a Waters
700 satellite WISp™ automatic injector and a Flo-One liquid scintillation spectrophotometer
(Radiomatic, Tampa, FL) as well as a Waters absorbance detector (254 nm). Scintillation fluid
was purchased from Beckman Coulter Inc. (USA). All other chemicals were of reagent grade and
purchased from either Sigma Chemical Co. or Merck Laboratory Supplies (South Africa).
4.2.2 Preparation of S. frutescens extracts
Dried, ground S. frutescens plant material, 18.6 g, was placed in a glass soxlet extractor fitted
with a double wall condenser [Swart et al., 1986, 1993; de Villiers, 1990]. The extractor was
fitted to a round bottom flask and the plant material was extracted with 250 ml methanol for ~8
hrs. The extract was dried at reduced pressure on a rotary evaporator at room temperature,
yielding 2.87 g dried plant material. The dried methanol extract was re-dissolved in 35ml de-
ionized water. An aqueous extraction was prepared by boiling dried plant material, 2.16 g, in de-
ionized water, 275 ml, for 30 min. The aqueous extract was lyophilized, yielding 0.624 g plant
material, and re-dissolved in 13 ml de-ionized water. The extracts were centrifuged at 6000 g for
5 min and the supernatants were stored at 4°C. The final concentration of the methanol and
aqueous extracts was 82 mg/ml and 48 mg/ml, respectively.
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GABA, pinitol and L-canavanine were dissolved in de-ionized water to a concentration of 1
mg/ml. The triterpenoid and flavonoid fractions4 of S. frutescens were also prepared. The
lyophilized flavonoid fraction was re-dissolved in de-ionized water and the lyophilized
triterpenoid fraction was re-dissolved in de-ionized water containing 0.1 % ethanol. Stock
solutions of 1 mg/ml and 5 mg/ml were prepared and stored at 4°C.
Sutherlandia tablets, 700 mg containing 300 mg dried leaf powder, were crushed to a fine
powder and dissolved in 5ml de-ionized water. The samples were incubated at 37°C for 1 hand
centrifuged at 3000 x g for 5 min. The supernatants were stored at 4°C till further use.
4.2.3 Preparation of adrenal mitochondria and microsomes
The mitochondrial and microsomal fractions were prepared as previously described by
Ming-Xue Yang & Arthur L. Cederbaum (1994). Fresh ovine adrenals were used for the
isolation of partially purified cytochrome P450 enzymes and all procedures were carried out in a
cold room at 4°C. The adrenals were decapsulated and 25 g adrenal cortex tissue was
homogenized in 75 ml io mM Tris-HCl buffer (pH 7.4) containing 1 mM EDTA and 0.25 M
sucrose, first in a Hamilton Beech blender and subsequently with a Potter-Elvejhem glass
homogenizer. The homogenate was centrifuged at 1000 x g for 20 min. The pellet was discarded
and the supernatant was centrifuged at 12000 x g for 15 min to sediment the mitochondria. The
mitochondrial pellet was washed by resuspension in 200 milO mM Tris-HCI buffer (pH 7.4)
containing 0.25 M sucrose, 1 mM EDTA and 1 % BSA and centrifuged at 12000 x g for 15 min.
The washing step was repeated twice as previously described. The washed mitochondrial pellet
was lyophilized overnight and the resulting ovine adrenal mitochondrial powder, 0.46 g, was
stored at -18°C.
PEG 8000 (50 % w/v) was slowly added to the supernatant containing the microsomal fraction to
a final concentration of 8.5 %. The mixture was stirred for 10 min at 4°C and centrifuged at
4 Donated by Prof. B-E van Wyk ,Dept. Botany, University of Johannesburg, South Africa.
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13000 x g for 20 min after which the supernatant was discarded. The pellet was subsequently
homogenized in 10 mM Tris-HCI buffer (pH 7.4) containing 150 mM KCI and 1 mM EDTA.
PEG (50 % w/v) was added to the suspension to a final concentration of 8.5 %, stirred for 10 min
at 4°C and centrifuged at 13 000 x g for 20 min. After repeating this step once more, the
microsomal pellet was resuspended in 80 milO mM Tris-HCI (pH 7.4) containing 0.25 M
sucrose and 1 mM EDTA, and stored in 5 ml aliquots at -80°C.
4.2.4 Determination of cytochrome P450 concentration
The cytochrome P450 content of the adrenal mierosomes and mitochondria was determined by
the carbon monoxide method described by Omura & Sato (1964).
The mitochondrial powder (2 mg/ml) was sonicated in 0.1 M phosphate buffer (pH 7.4)
containing 10 % ethylene glycol, in an ice slurry for 5 min with one minute intervals. The
sonicate was subsequently saturated with carbon monoxide, divided into 2 optically matched
cuvettes and a baseline recorded between 400 and 500 nm. Sodium dithionate (1-2 ug) was
added to the sample cuvette and the spectrum recorded. The spectra were monitored for ~ 10 min
until the spectrum was completely developed.
The microsomal suspension was diluted (1:3) in 0.1 M phosphate buffer and the carbon
monoxide induced difference spectrum of the microsomal preparation was carried out in the
same manner. A molar extinction coefficient (e) of91 cmimlvl", as reported by Omura and Sato
(1964), was used to determine the cytochrome P450 concentration (c) from the equation below.
dA = tcl
!1A is the change in absorbance, c is the concentration of the solution and I is the path length
through the solution (1 cm) [Wilson and Walker, 2000]. The protein concentration of the
microsomal and mitochondrial preparations was determined using the Pierce BCA Protein Assay
Kit (perstorp Life Sciences Company, IL, USA).
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4.2.5 Spectral binding assays
Assay A: Inhibitor-induced difference spectra
The assays were carried out to determine whether the test components were able to bind to
adrenal cytochrome P450 enzymes using microsomal preparations. The micro somes were diluted
in 0.1 M phosphate buffer, (pH 7.4) containing 10 % ethylene glycol to a cytochrome P450
concentration of 0.6 )lM (7.9 mg protein). The assays were carried out at room temperature in a
final reaction volume of 1 ml using four optically matched cuvettes, two reference cuvettes and
two sample cuvettes, in tandem'. The test component (methanol and aqueous extracts (to a final
concentration of 4.1 mg/ml and 2.4 mg/ml respectively), tablet extracts (0.3 mg/ml) and
bioactive compounds (0.05 mg/ml)) was added (50 ul) to one reference and one sample cuvette
which contained 0.2 M phosphate buffer. The remaining two cuvettes contained the enzyme
preparation. A baseline was recorded between 360 nm and 500 nm. Prior to recording the
binding spectrum, the test component in the sample cuvette was replaced with 0.2 M phosphate
buffer. Test component was subsequently added to the enzyme preparation in the sample cuvette
and an equal volume of buffer was added to the enzyme preparation in the reference cuvette.
Spectra were recorded over a period of 30 min until the spectrum was completely developed.
Assay B: Inhibition of steroid-induced difference spectra
These assays were done to determine whether the test components were able to inhibit the
binding of endogenous steroids to the mitochondrial and microsomal P450 enzymes. Reactions
were carried out at room temperature in a final reaction volume of I ml [Swart et al., 1993;
2003]. The cytochrome P450 concentration was 0.78 )lM and 0.35 )lM in the mitochondrial and
microsomal preparations, respectively. The inhibitory effects of the test components on the
steroid-induced difference spectra, were determined by adding 5 ul - 150 ul (to a final
concentration of 0.24 mg/ml - 12.3 mg/ml) of the extracts and compounds (0.05 mg/ml - l.5
mg/ml) to the enzyme preparations. Equal volumes were subsequently divided into 2 optically
5 The tandem configuration for reference and sample cuvettes was required to eliminate the absorbance the test
components exhibited in the Soret range (personal communication P Swart)
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matched cuvettes and a baseline was recorded between 360 and 500 nm. The steroid substrates,
PREG, PROG and DOC, dissolved in ethanol, were added to the sample cuvette to a final
concentration of 3.2 ).lM.An equal volume of ethanol was added to the reference cuvette. The
cuvettes were inverted gently and the spectra recorded.
The substrate-induced difference spectrum of CYPl7 and CYP21 was determined with PREG
and PROG as substrate in the microsomal suspensions. The substrate-induced difference
spectrum of CVP 11B1 was determined in the same manner using DOC as a substrate in the
mitochondrial suspension. These spectra were recorded using plant material (final concentrations
of 0.24 mg/ml - 12.3 mg/ml) and tablet extracts (3 mg/ml), the triterpenoid (0.05 -1.5 mg/ml)
and flavonoid fractions (0.05 -0.15 mg/ml), L-canavanine (0.05 - 0.15 mg/ml), GABA (0.05 -
0.15 mg/ml) and pinitol (0.05 - 0.15 mg/ml). The control substrate-induced difference spectra
were recorded in the absence of the test components. Inhibition was indicated by a reduction in
the amplitude of the peaks - a decrease in the absorbance maximum at 383 nm and an increase in
the absorbance minimum at 416 nm. The inhibitory effect may be calculated as follows:
% inhibition = 100 - ((t/c) x I00), where t = absorbance at 390 nm minus absorbance at 420 nm
in the presence of inhibitory component and c = absorbance at 390 nm minus abs at 420 nm in
the absence of inhibitory component.
4.2.6 Steroid conversion assays
Assay A: steroid conversion assays in adrenal mierosomes
Steroid substrate conversion assays serve as a measure of biological activity and were thus
conducted to determine if S. frutescens was able to influence the conversion of steroid substrates
in the microsomal preparations. The metabolism of PREG and PROG was assayed in ovine
adrenal mierosomes as previously described [Swart et al., 1995; 2002]. The assay was carried
out in a final volume of 1 ml in a shaking water bath at 37°C. Radio-labelled tritiated steroid
(50000 cpm/50 ul) and steroid solution (10 ).lM) were pipetted onto filter paper, placed in a
microcentrifuge tube and dried under nitrogen. Once the organic solvents had been evaporated,
50 mM Tris buffer (PH 7.4) containing 50 mM NaCI and 1% BSA, microsomal preparation (0.35
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ulvl P450, 3.96 mg protein), 10 mM MgCb and isocitrate (2 mg/ml) was added to the dried
steroids. The mixture was preincubated for 5 min at 37°C and the reaction initiated by the
addition of isocitrate dehydrogenase (0.4 U/ml) and NADPH (l mM). The inhibitory effect S.
frutescens was assayed by the addition of the test components in a 50 ul volume (50 ul buffer or
solvent in the control assay) to the reaction mixture prior to the initiation of the reaction. With
the addition of 50 )lI of the extracts to the assay, the final concentration of the dried plant
material in the presence of the methanol and aqueous extract was 4.1 mg/ml and 2.4 mg/ml,
respectively. The addition of 50 )lI of a 5 mg/ml stock solution of the triterpenoid fraction
resulted in 0.25 mg/ml final concentration while the addition of 50 ul of S. frutescens tablet
extracts represented a final concentration of 3 mg/ml dried plant material. At specific time
intervals (0, I, 2, 5 and 10min) 50 ul aliquots were removed and pipetted into glass tubes
containing a cold mixture of 5ml dichloromethane and 450 ul de-ionized water. The steroid
metabolites were extracted by vortexing the mixture for 2 min and the organic and water phases
separated using a bench centrifuge at medium speed. The water phase was subsequently
aspirated and the dichloromethane evaporated under nitrogen. The steroid products were
redissolved, in 120 )lI methanol for HPLC analysis.
Assay B: steroid conversion assays in COSl cells
Since microsomal preparations contain both CVP 17 and CYP21, the influence of S. frutescens
on these individual enzymes was investigated by expressing the recombinant enzymes in COS 1
cells, a non-steroidogenic mammalian cell line. The lyase activity of the CYP]7 enzyme is
species specific and steroid conversion was thus investigated with CVP 17 enzymes from
different species to establish if S. frutescens had specific effects on the hydroxylase or lyase
activity of the enzyme.
Maintenance of COS 1cells
All incubations were carried out at 37°C and cells were maintained at 5 % CO2 and 90 %
humidity. All additions or removal of media were performed in sterile conditions in a laminar
flow hood. A freezing vial containing ] ml COS 1 cells was thawed in hand and resuspended in
]0 ml of culture medium (DMEM, high glucose containing 0.15 % NaHC03, 10 % Fetal calf
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serum and 1 % penicillin streptomycin solution) warmed to 37°C. The suspension was plated
into a 100 mm culture dish and incubated. The culture medium was replaced daily with 10 ml
warmed culture media until the cells were confluent (4 days). Confluency was greater than 80 %.
The cells were split into 5 x 100 mm culture dishes as follows: The medium was removed from
the 100 mm culture dish and washed with 1 ml warm tripsin-EDTA medium (10 % trypsin-
EDTA and 10 % Dulbecco's phosphate buffered saline, without calcium and magnesium). The
cells were incubated at room temperature with 1 ml tripsin-EDT A medium for 3 min before
collecting the cells (> 80 % confluency). The cells were subsequently resuspended in 50 ml
culture media and 10 ml was plated into each of the 5 culture dishes.
Freezer stocks were prepared by collecting cells in culture media (50 ml/100 mm dish), as
described above. The cell suspension was pi petted into a conical centrifuge tube and centrifuged
at 500 x g for 5 min. The media was removed and the cells were resuspended in culture medium
containing 10 % DMSO, 3 millOO mm dish. Aliquots, I ml, were frozen at -80°C for 48 hours
and subsequently transferred to liquid nitrogen and stored till further use.
Transfection of COS 1cells
Cells were split one day prior to transfection, as described above. On the following day the
culture media was removed and each culture dish was washed with 2 ml warmed transfection
medium (DMEM, high glucose containing 0.15 NaHC03, 1 % penicillin streptomycin solution,
20 mM HEPES, pH 7.4). The cells were subsequently incubated for 1 h in 2 ml transfection
media containing 0.25 mglml DEAE-dextran and 10 ug/rnl plasmid DNA. The following
plasmid constructs containing the recombinant DNA encoding the cytochrome P450 enzymes
were assayed: baboon CYP17/pTarget, ovine CYP17/pcDNA 3.1, human CYP171 pcD and
bovine CYP211pCMV. The transfection media was removed and 10 ml culture media containing
chloroquine, 52 ug/ml, was added to each dish and incubated for 5 h. Each culture dish was
subsequently washed with 5 ml culture media and incubated with 10 ml fresh culture media. The
culture media was replaced daily. Transfected cells were split into 12 well plates 48 h after
transfection, as previously described. Cells from 1 x 100ml11 were resuspended in 12 ml culture
media and 1 ml cell suspension was plated per well. Cells were incubated for 24 h before the
addition of the substrate.
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Substrate addition and conversion assay
The culture media was removed and the enzymatic reactions were initiated by the addition of 1
ml culture medium containing the appropriate steroid substrate (1 JlM) together with tritiated
steroid (100 000 - 200 000 cpm/ml). A dilution range (1-1000 X) of the S. frutescens extracts
was made in de-ionized water and comprised 0.2 ml of the I ml volume of the substrate
containing culture medium added to the cells and incubated for 12 - 24 h. The extracts were
redissolved in de-ionized water, the influence of the presence of this volume of extract was
determined by substituting 0.2 ml of the substrate containing culture medium with the de-ionized
water which served as the control. In addition the following transfection controls were included
to ensure that the metabolism of the steroids were the result of the presence of the expressed
enzyme: a mock transfection in which no plasmid was added to the transfection media and a
transfection in which cells were transfected with a vector containing no recombinant DNA.
Substrate conversion in the absence and presence of S. frutescens extracts was assayed by
removing 0.1 ml media at over a period of 24 h and extracting steroid metabolites with 5 ml
dichloromethane as previously described (section 4.2.6, Assay A). Samples were vortexed and
centrifuged after which the aqueous phase was aspirated and dichloromethane phase dried under
nitrogen. The dried steroid residues were subsequently redissolved in 120 JlI methanol,
transferred into WISP™ vials and subjected to HPLC analysis.
COS 1cells viability assay
The viability of the COS 1 cells exposed to Sutherlandia extracts was assessed by monitoring the
detachment of cells from tissue culture dishes after prolonged (24 h) contact with the plant
extracts", The experiments were conducted as follows. The methanol and aqueous extracted plant
material were resuspended in water and sterile filtered (0.22 urn), COS 1 cells (26mm culture
dish) were incubated with extracts (4.1 mg/50 JlI methanol extract and 2.4mg/50 ~L1aqueous
extract, respectively) for 24 hours, the media was removed and the culture dishes were washed (3
times) with PBS (lml per well) to remove detached cells. The attached, viable cells were
subsequently collected with a cell scraper and resuspended in PBS (3 ml). COS cells incubated
6 http://www.jingmei.com/site/site/zt/Roche/FuGENE%206%20 Feature%20Presentation. pdf
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without extracts served as a control and were treated in the same manner. The cells were washed
by centrifugation at 500 x g for 5 min, aspirating the PBS supernatant and re-suspending the cells
in 1 ml PBS. This was repeated 3 times to remove all traces of culture medium. The cell
suspensions were subsequently homogenised with a mini Potter Elvejham homogeniser (1 ml)
and the protein concentrations for each incubation determined using the Pierce BCA Protein
Assay Kit (Perstorp Life Sciences Company, IL, USA).
4.2.7 HPLC analysis of steroid metabolites
PREG metabolites were separated using a Novapak'" C8 column at a flow rate of 1 ml/min
[Swart et al., 1995; 2002]. The mobile phase consisted of solvent A (50:48.5: l.5
water/acetonitrile/isopropanol) and solvent B Cl 00 % acetonitrile). Metabolites were eluted from
the column with solvent A for 5 min followed by a linear gradient from A to 100 % B in 3 min
and an isoeratic elution with solvent B for 3 min.
The PROG metabolites were separated on a Novapak" C 18 column at a flow rate of 1 ml/min.
Two mobile phases, solvent A (65:35 methanol/water) and solvent B (100 % methanol) were
used to achieve the desired resolution of the steroids [Swart et al.,1995; 2002]. The metabolites
were eluted from the column with solvent A for 15 min followed by a linear gradient from A to
100 % B in 5 min and an isoeratic elution with solvent B for 5 min.
The tritiated steroids were detected with a radioactive flow detector and the areas under the
individual peaks of steroid metabolites were integrated and expressed as a percentage of the total
radioactivity. The inhibition of conversion may be calculated as follows:
% inhibition = 100 - ((t/c) x 100), where t = % conversion or formation of steroid in the presence
of the inhibitory component and c = = % conversion or formation of steroid in the absence of
inhibitory component.
Stellenbosch University http://scholar.sun.ac.za
69
4.2.8 Liquid chromatography-Mass spectrometry of S. frutescens extracts.
LC-ESMS was performed with a Micromass Quattro hyphenated quardropole time-of-flight
mass spectrometer. A capillary voltage of 3.5 kV was applied with a source temperature of
100°C. The cone voltage was set at 35 V. Data acquisition was in the negative mode through the
m/z = 100 -1999 scan range. A10).l1 injection of the aqueous samples was separated on a
Waters Alliance HPLC fitted with a Luna Gemini Cl8 (5 urn, 30 x 2 mm) column. Two solvents
were used to obtain the desired separation; solvent A, de-ionized water containing 0.1 % formic
acid and Solvent B, 100 % acetonitrile. Separation was obtained with the gradients shown in
Table 1. A flow rate of I ml/min was applied with a split of 4: 1 directed to the mass spectrometer
and the rest to a photo diode array detector (scanning from 220 nm - 550 nm).
Table 1. Gradient table for HPLC separation of Ss frutescens extracts
Time Solvent A Solvent B
0.00 98.0 2.0
30.00 0.0 100.00
35.00 0.0 100.0
35.01 98.0 2.0
45.00 98.0 2.0
4.2.9 Statistical analysis
Results are expressed as the mean with error bars representing the standard errors of the means
(SEM). The Student's paired t-test was used to compare the means of two groups using
GraphPad Prism version 4.00 for Windows, GraphPad Software, San Diego California USA,
www.graphpad.com ...
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4.3 Results
The biological activity of S. frutescens extracts, single compounds and tablets were investigated
by determining their ability to bind P450 enzymes, with the subsequent induction of a type " or a
reverse type I spectrum, as well as the influence of the test components on the binding of
substrates to the P450 enzymes. As discussed previously, the three types of spectra, type I, type
TI and reverse type I (modified type TT),shown in Figure l , may be identified by changes in the
UV spectrum. Ligand free cytochrome P450 exhibits an absorption maximum at ~420 nm since
the ferric iron is in a low spin state. A typical type I binding spectra, achieved upon binding to
the substrate, exhibits a reduced absorption at 420 nm and a corresponding increased absorption
maximum at 390 nm. The binding of substrate to the enzyme is characterised by a change from
the low spin to the high spin state of the ferric iron. Compounds which interfere with the binding
of the substrate or prohibit the substrate from binding will result in an increase in the absorption
at 420 nm and a decrease in the absorption at 390 nm. Inhibitors binding directly to the ferric
iron, replacing the water molecule as the sixth axial ligand, will induce a type II spectrum. This
spectrum is characterised by an increase in the absorption between 425 nm and 435 nm and a
decrease in the 390 nm maximum, due to an increase in the low spin state of the ferric iron. The
reverse type T spectrum is characterised by an increase in the 420 nm band and a decrease in
absorbance at 390 nm. It is possible that these changes may result from the ligand binding to the
enzyme but does not, however, result from direct binding to the ferric iron.
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Figure 1. Typical example of difference spectra obtained by the addition of a substrate or an inhibitor, to
cytochrome P450 enzymes. A, type I difference spectrum; B, type Jl difference spectrum and C, reverse type
I difference spectrum 7.
7 Prof. P. Swart, Biochemistry Department, University of Stellenbosch, South Africa.
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The cytochrome P450 content of ovine adrenal mitochondrial and microsomal preparations was
determined by the carbon monoxide induced difference spectra [Omura and Sato, 1964]. The
P450 enzyme content of the adrenal cortical fractions was determined using the millimolar
extinction coefficient as described by Omura and Sato (1964). The carbon monoxide induced
difference spectra of solubilised cytochrome P450 in the mitochondrial and microsomal
adrenocortical fractions are shown in the Figures 2A and B, respectively. The absorbance at 450
nm is allowed to develop completely since the intensity increases with time after the addition of
sodium dithionite. The slow formation of the peak at 450 nm is due to the slow reduction of
cytochrome P450. These spectra exhibit peaks at about 450 nm and deep troughs at about 410
nm.
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Figure 2. Sodium dithionate reduced carbon monoxide difference spectra of the ovine adrenocortical
mitochondrial preparation (A), [cytochrome P4501 = 0.78 11M(1.189 nmol P450/mg protein) and the ovine
adrenocortical microsomal preparation (B), [cytochrome P4501 = 0.442 11M(0.075 nmol P450/mg of protein).
The P450 enzyme content of the adrenocortical mitochondria was 1.189 nmol P450/mg protein
and that of the microsomal fraction was 0.075 nmol P450/mg of protein. The mitochondrial
preparation contained CYPl1A, CYPIIBI and CYPIIB2 while the microsomal fraction
contained the CYP17, CYP21 and 3~HSD steroidogenic enzymes. Due to unfavourable
experimental conditions, such as the use of ionic detergents, cytochrome P450 may be converted
to cytochrome P420, its inactive form, displaying a peak at 420 nm. The peak observed in Figure
2B at 424 nm is due to cytochrome b5. Cytochrome b5 can mediate the transfer of the second
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electron to the oxygenated cytochrome P450 complex and may be involved in the regulation of
adrenal microsomal steroid hydroxylase activities by changing the rates of CYP2] and CYP 17
reactions. When cytochrome b5 is reduced by dithionate, the Soret maximum shifts to 423 nm
[Yang and Cederbaum, 1994].
4.3.1 Inhibition of cytochrome P450 enzymes by S. frutescens extracts
4.3.1.1 Spectral assays
Aqueous and methanol extracts of S. frutescens were dried and redissolved in water and 50 ul
aliquots were subsequently used to carry out all spectral assays. It was found that 5 ul of the
extracts (0.41 mg/ml and 0.24 mg/ml final concentration of the plant material in the presence of
the methanol and aqueous extract, respectively) did not exhibit any marked inhibition while
complete inhibition of the cytochrome P450 enzymes was observed in the presence of 100 )lI
(8.2 mg/ml and 4.8 mg/ml, respectively) of the extracts. The recommended daily dose for an 80
kg individual is 720 mg (9mg/kg/day) dried plant material [Seier et al., 2002] based on the
recommendations of the commercially available S. .frutescens tablets. Aliquots (50 ul) of the
methanol and aqueous extracts used in the in vitro assays contain 4.1 mg and 2.4 mg of the dried
plant material, respectively, which is substantially less than the in vivo recommended dosage.
Spectral Assay A
The microsomal preparation was incubated with 50 ul (methanol and aqueous extracts contain
4.1 mg and 2.4 mg of the dried plant material, respectively) extract to determine if compounds
present in the plant extracts interact with the cytochrome P450 enzymes. It would appear that,
with the addition of the aqueous extract, the cytochrome P450 enzymes exhibit a reverse type I
difference spectrum (Figure 3) with an absorbance maximum at 414 nm. The absorbance
minimum, was, however, not clearly detectable as a result of the pigmentation of the extract 8.
The difference spectrum induced by the methanol extract could not be clearly detected due to
interference of pigments in this absorbance range.
8 Personal communication Prof. P. Swart, Biochemistry Department, University of Stellenbosch, South Africa.
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The induction of the reverse type I spectrum firmly suggests that compound(s) in the aqueous
extract interact with the microsomal P450 enzymes. It can thus be deduced that compound(s)
influence the ferric iron, displacing the water molecule in the active site resulting in an increase
in the low spin state of the ferric iron. Furthermore, it is unlikely that the reverse type 1 substrates
bind directly to the heme to displace the water molecule and rather bind to a site in the heme
pocket [Lewis 1996].
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Figure 3. Reverse type Tspectrum of microsomal cytochrome P450 enzymes ([cytochrome P4501 = 0.35 ,..M)
induced by the aqueous extract, 50,..1 (final concentration 2.4 mg/ml).
Spectral Assay B
Since the aqueous extract interacted with the P450 enzymes, the effect of this interaction on the
binding of native steroid substrates to the enzymes was investigated. The binding of
deoxycorticosterone (DOC) to eYP1IB1, a mitochondrial P450 enzyme, induced a type I
spectrum as illustrated in Figure 4A. Although the binding of the methanol extract to the P450
enzymes could not be shown the inhibition of pregnenolone (PREG) and progesterone (PROG)
binding to the microsomal P450 enzymes was nevertheless investigated and results are
summarized in Figure 4B. DOC binding to the mitochondrial P450 enzymes was inhibited (> 60
%) by both extracts (P < 0.005). Inhibition of PREG binding «10 %) was not significant (P =
0.25) while PROG (>52 %) binding to the microsomal enzymes was inhibited by both the
methanol and aqueous extracts CP< 0.02).
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Figure 4. (A) Inhibition of the DOC-induced type Tdifference spectra in adrenal mitochondria (cytochrome
IP4501 = 0.78 IlM). DOC (3.2 IlM); DOC + methanol extract (final concentration 4.1 mg/ml) and DOC +
aqueous extract (final concentration 2.4 mg/ml). (B) Percentage inhibition of DOC (3.2 IlM) binding to
CYPIIBl, and PROG (3.2 IlM) and PREG (3.2 IlM) binding to microsomal P450 enzymes (cytochrome
IP4501 = 0.35 IlM), by 50 III methanol and aqueous extracts (final concentration 4.1 mg/ml and 2.4 mg/ml,
respectively). Results are presented as the mean, error bars represent SEM and n = 3.
4.3.1.2 Inhibition of steroid conversion
Conversion Assay A
The interactions of the extracts with the P450 enzymes prompted further investigations into the
influence of the extracts on the catalysis of steroid substrates by both the ovine adrenal
microsomal enzymes, CVP 17 and CYP21. Although there was strong inhibition of DOC binding
to the mitochondrial P450 enzymes, the influence of the extracts on the catalytic activity of
CVP 17 and CYP21 was investigated since the inhibition of binding results pointed to different
inhibitory activity towards the two microsomal enzymes. Furthermore, CVP 17 is at a branch
point in glucocorticoid and androgen biosynthesis. Inhibition of the lyase activity of CVP 17
would result in the production of the glucocorticoids. Inhibition of CYP21 activity would inhibit
the production of the glucocorticoids and shift steroid biosynthesis to the production of
androgens.
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With the addition of PROG to the microsomal preparation both the P450 enzymes, CVP 17 and
CYP21, catalyse the conversion of the steroid substrate. CYPI7 converted PROG to 17-0H-
PROG, while CYP21 converted both PROG and 17-0H-PROG to DOC and deoxycortisol,
respectively, as shown in Figure 5A where conversion was monitored in the absence of extracts.
Five minutes after the initiation of the reaction, 23 % PROG was converted to DOC, 37 % was
converted to deoxycortisol, 10 % PROG was represented by 17-0H- PROG while 30 % PROG
remained. HPLC analysis of the steroid metabolites is illustrated in Figure 7A. In the presence of
50 ~tl methanol and aqueous extracts (final concentration 4.1 mg/ml and 2.4 mg/ml,
respectively), the steroid metabolism was inhibited as illustrated in Figure 5B. DOC metabolism
appears most markedly inhibited by both methanol (93.6 %) and aqueous (71 %) extracts
suggesting that compounds in the extracts inhibit CYP21 more than CYP17 (P < 0.003). The
inhibition of DOC formation by the aqueous extract was three times greater than the inhibition of
17-0H-PROG and the inhibition of deoxycortisol (45 %) formation is also greater (P < 0.01)
than the inhibition of 17-0H-PROG (21 %). In the presence of the methanol extract, however,
17-0H-PROG formation is inhibited more than deoxycortisol formation, 68 %, and 50 %,
respectively. Thus it would appear that the aqueous extract is a more potent inhibitor of CYP21
than the methanol extract, when compared to their inhibitory effects on CYP17.
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Figure 5. (A) Metabolism of PROG (10 11M)by ovine adrenal mierosomes (cytochrome IP4501 = 0.35 11M)
after initiation with NADPH (ImM). (B) Percentage inhibition of steroids (after 10 min) in the presence of
50111methanol and aqueous extracts (final concentration 4.1 mg/ml and 2.4 mg/ml, respectively). Results are
presented as the mean, error bars represent SEM and n = 3.
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In most species studied to date, CYP17 catalyses the conversion of PREG to 17-0H-PREG and
dehydroepiandrostenedione (DHEA). Ovine CYP17, however, does not exhibit significant lyase
activity for 17-0H-PREG, as seen when PREG was added to ovine adrenal microsomes, in the
presence of trilostane, a 3~HSD inhibitor (Figure 6A). HPLC analysis shows that only 17-0H-
PREG is formed and negligible amounts of DHEA was detected (Figure 7B). After 14 min, 32.6
% PREG was converted to 17-0H-PREG, this conversion was significantly inhibited (P < 0.01)
in the presence of 50 !-LImethanol and aqueous extracts (final concentration 4.1 mg/ml and 2.4
mg/ml, respectively) by 77 % and 49 %, respectively (Figure 6B).
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Figure 6. (A) Metabolism of PREG (10 ,..M) by ovine adrenal mierosomes (cytochrome [P4501 = 0.35 ,..M)
after initiation with NADPH (ImM). (B) Percentage inhibition of steroids in the presence of 50 ,..1 methanol
and aqueous extracts (final concentration 4.1 mg/ml and 2.4 mg/ml, respectively). Results are presented as the
mean, error bars represent SEM and n = 3.
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Figure 7. HPLC analysis of steroid metabolism by ovine adrenal mierosomes at 10 min. (A), PROG
metabolism (10 ,..M). Peak 1, PROG (23 min); peak 2, 17-0H-PROG (19.5 min); peak 3, DOC (16.8 min); and
peak 4, deoxycortisol (10 min). (B) PREG metabolism (10 ,..M). Peak 1, PREG (7.5 min); peak 2, 17-0H-
PREG (3.5 min); and peak 3, DHEA (2.2 min).
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The aqueous extract similarly inhibited the conversion of PREG (49 %) and PROG (49 %). The
methanol extract also inhibited PREG (77 %) and PROG (71 %) metabolism similarly.
Interestingly, although the extracts did not inhibit PREG binding to the microsomal P450
enzymes, PREG metabolism was inhibited.
Conversion Assay B
COS 1 cells were transfected with cDNA encoding CVP] 7 and CYP21 to investigate the
inhibitory effects of S. frutescens extracts on the individual cytochrome P450 enzymes. To
ensure the inhibition of steroid conversion observed was a result of inhibition of the enzyme and
not a decrease in viability of the cells, the protein concentration of the attached cells was
determined. Jf the presence of the extracts resulted in the death of the COS 1 cells, the cells
would have detached from the surface of the dish resulting in a lower protein concentration
compared to that of the control. The protein concentration of the control plate averaged at
approximately 0.587 mg/ml while in the presence of 50 ul of the extracts the protein
concentration was an average of 0.609 mg/ml. There were no significant differences in protein
concentrations observed (P = 0.7) in the presence of 50 ul of the extracts, suggesting that the
presence of the extract did not reduce the viability of the cells, thus the presence of the extracts
inhibited the enzymes and were not toxic.
The CYP 17 enzyme catalyses the conversion of both PROG and PREG to their respective
hydroxysteroids in all species. The lyase activity of the CYP17 enzyme, which converts 17-0H-
PREG to DHEA and 17-0H-PROG to androstenedione (A4), is however species specific and
underlies the complexity of this enzyme in the regulation of steroid biosynthesis. The
hydroxylase activity for PREG and PROG has been shown for all species investigated to date but
the lyase activity for the hydroxysteroid intermediates differs [Swart 1998]. For example, human
and bovine CYP 17 catalyses the conversion of 17-OH-PREG to DHEA but not the conversion of
17-0H-PROG to A4 [Chung et al., 1987; Zuber et al., 1986]. Guinea pig CYP17, in contrast,
catalyses the conversion of 17-0H-PROG to A4, but not the conversion of ] 7-0H-PREG to
DHEA. Rat, mouse and chicken CYP17 catalyses the lyase reactions of both 17-0H-PREG and
17-0H-PROG [Fevold et al., 1989]. Interestingly, although ovine CYP17 does not exhibit lyase
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activity for 17-0H-PREG in microsomal preparations, it does catalyse the reaction in HEK293
cells [Swart et al., 2002].
As a result of these distinct catalytic differences, the influence of S. frutescens extracts on the
catalytic activity of CYPI7 in different species was investigated; baboon CYPI7, ovine CYPI7
and human CYPI7. Since PROG and 17-0H-PROG are also substrates for the CYP21 enzyme
which catalyses the conversion of PROG to DOC and 17-0H-PROG to deoxycortisol, the
influence of S. frutescens extracts on the activity of bovine CYP21 was also assayed.
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Figure 8. Percentage inhibition of PREG (lI-1M) and metabolites in COS 1 cells expressing baboon CYP17, in
the presence of methanol and aqueous extracts (50 1-11;final concentration 4.1 mg/ml and 2.4 mg/ml,
respectively; and 251-11;final concentration of 2.05 mg/ml and 1.2 mg/ml, respectively). Results are presented
as the mean, error bars represent SEM and n = 3.
Baboon CYPI7 converted PREG to 17-0H-PREG and DHEA. In the absence of inhibitor 38 %
PREG was converted to 17-0H-PREG and 42 % to DHEA after 24 h. In the presence of 50 ~L1
methanol (4.1 mg/ml) extract, both the lyase and hydroxylase activity of baboon CVP 17 are
inhibited. However, in the presence of 25 ul methanol extract (2.05 mg/ml) the hydroxylase
activity is more significantly (P < 0.001) inhibited (Figure 8). The aqueous extract also inhibited
the production of DHEA to a lesser degree than the production of 17-OH-PREG (81.9 %
inhibition), suggesting that compounds in the aqueous extract have a greater potential to inhibit
the hydroxylase activity (P < 0.01) of CYPI7 (Figure 8). With respect to the plant material
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extracted, 25 ).lIof the methanol extract is comparable to the concentrations of plant material in
50 ul of the aqueous extract, 2.05 mg/ml and 2.4 mg/ml, respectively. Thus, from results
presented in Figure 8, the aqueous extract exhibits stronger inhibition of CVP 17 (P < 0.05) than
the methanol extract. The inhibition of the hydroxylase activity in the presence of 25 ul methanol
extract and 50 ul aqueous extract is similar while the inhibition of the lyase activity of the
enzymes is four times more in the presence (P < 0.02) of the aqueous extract.
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Figure 9. Percentage inhibition of steroids in COSI cells expressing ovine CYP17 in the presence of 50 1-11
methanol and aqueous extracts (final concentration 4.1 mg/ml and 2.4 mg/ml, respectively). (A) PREG (1
I-1M)and metabolites, (B) PROG (1 I-1M) and metabolites. Results are presented as the mean, error bus
represent SEM and n = 3.
In the COS I cells, ovine CYP17 catalysed the conversion of both PROG and PREG to their
respective C 19 steroids via their respective hydroxysteroid intermediates. Ovine CVP 17
converted 44 % PREG to DHEA after 8 h, while the production of A4 from 17-0H-PROG was
detectable only after ~ 12 h. After 24 h, 26.5 % PROG was metabolised to A4 and 17.5 % to 17-
OH-PROG, in the absence of the extracts. Figure 9 illustrates the inhibition of the metabolism of
PREG and PROG by both the extracts. The methanol extract showed no significant difference in
the inhibition of the two substrates (P = 0.126). In addition, although the methanol extract
appears to inhibit the lyase and hydroxylase activity of the CVP 17 enzyme to a similar degree,
assays carried out at lower concentrations of methanol extracts would determine the extracts'
true inhibitory potential of the hydroxylase/lyase activity of the enzyme. Since the aqueous
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extract shows significant inhibition (P < 0.002) of the formation of the hydroxysteroid
intermediates, it would appear that compound(s) present in the aqueous extract exhibited a
greater inhibitory effect on the hydroxylase activity of ovine CYP17.
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Figure to. Percentage inhibition of steroids in COSt cells expressing human CYP! 7 in the presence of
methanol and aqueous extracts (5 Ill, final concentration 0.41 mg/ml and 0.24 mg/ml, respectively; and 50 ul,
final concentration 4. t mg/ml and 2.4 mg/ml, respectively. (A) PREG (1 f.lM)and metabolites and (8) PROG
(I f.lM)and metabolites. Results are presented as the mean, error bars represent SEM and n = 3.
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Figure Il. HPLC analysis of PROG metabolism by human CYP17 at 6 h. Peaks on the chromatogram are: I,
PROG (20 min); 2, 17-0H-PROG (14.3 min); 3, 16-0H-PROG (7.3 min).
Human CVP 17 exhibited both 17a-hydroxylase and lyase activity, converting PREG to 17-OH-
PREG and subsequently DHEA. After 24 h, 19 % PREG was converted to 17-0H-PREG and 25
% to DHEA. Jn the presence of S. frutescens extracts, PREG and PROG metabolism were
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inhibited as illustrated in Figure lOA and lOB, respectively. The methanol extract inhibited both
the hydroxylase and lyase activity of human CYP 17 to a similar degree. The aqueous extract also
had no significant difference (P = 0.065) in inhibitory activity of the two activities of the
enzymes (Figure lOA). Progesterone was converted to its hydroxysteroid intermediate and
androstenedione was not detected. Human CYP17 exhibits both 17a-hydroxylase activity and
16a-hydroxylase activity with PROG thus being converted to both 17-0H-PROG and 16-0H-
PROG [Swart et al., 1993]. HPLC analysis of these steroid metabolites is presented in Figure Il.
The conversion of PROG was inhibited in the presence of both the methanol (71 %) and aqueous
extracts (57 %), both with a stronger inhibition (P < 0.05) of the 16-hydroxylase activity.
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Figure 12. Metabolism of PROG (1 !lM) by bovine CYP21 expressed in COS I cells. (A) HPLC analysis of
PROG metabolites after 6 h. Peak 1 is PROG (22.7 min) and peak 2 is DOC (19.5 min). (B) Percentage
inhibition of PROG metabolites in the presence of 50 ul of the methanol and aqueous extracts (final
concentration 4.1 mg/ml and 2.4 mg/ml, respectively). Results are presented as the mean, error bars represent
SEM and n = 3.
Bovine CYP21 converts both PROG and 17-0H-PROG to DOC and deoxycortisol, respectively.
When PROG was given as a substrate, ~50% was converted to DOC after 24 h. HPLC analysis
of steroid metabolites assayed in the absence of extracts is shown in Figure 12A. In the presence
of methanol and aqueous extracts, PROG conversion was inhibited by 95 % and 66 %,
respectively (Figure 12B).
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4.3.1.3 Liquid chromatography-Mass spectrometry of S. frutescens extracts
Le-MS analyses of the methanol and aqueous extracts showed that the samples comprised a
similar but complex mixture. Marked differences in the water extracts, prepared at 1000e and
sooe, were noticed. It is evident that the aqueous extraction carried out at 100oe, yielded a
similar Le-MS elution profile as the methanol extract. Water extraction under reduced pressure
at sooe, however, did not yield the two prominent fractions seen at retention times between 5.38
and 6.06 min for the methanol and the aqueous extracts prepared at 100°e.
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Figure 13. Analysis of methanol extracts of S. frutescens (A) UV chromatogram and (B) Total ion
chromatogram (ESI negative) 0-15 min.
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Figure 14. Analysis of aqueous extracts of S. frutescens (A) UV chromatogram and (8) Total ion
chromatogram (ESf negative) 0-]5 min.
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Figure 15. Analysis of aqueous extracts of S. frutescens prepared at 50°C under reduced pressure (A) UV
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Interestingly the two components, identified by Tai et al. (2004), with molecular weights of 740
(peaks at 5.38 min and 5.58 min) and 724 (peaks at 6.06 min), were confirmed by negative ion
electrospray mass spectrometry (Figure 13 and 14). These two compounds were not observed in
the aqueous extract carried out at the lower temperature (Figure 15). The combination of
e1ectrospray mass spectrometry in the negative mode, combined with UV may indicate the
presence of flavonoids. Phenolic compounds, such as flavonoids, have the ability to be
negatively ionized while at the same time some conjugated double bonds or aromatic rings
present in the structure absorb in the aromatic region. The hydrophobic compounds eluting later
exhibiting little absorbance in the UV range would include the more complex flavonoids and
possibly the triterpenoids.
4.3.2 Inhibition of cytochrome P450 enzymes by bioactive compounds in S.
frutescens
In S. frutescens, L-canavanine, pinitol, GABA, triterpenoids as well as flavonoids have been
identified as bioactive compounds having medicinal properties, An investigation was therefore
carried out to determine whether these compounds were able to interact with cytochrome P450,
The ability of these compounds to induce a difference spectra as well as their ability to influence
substrate binding was assayed. The influence of the triterpenoid fraction on the catalytic activity
of cytochrome P450 was assayed in adrenal microsomes.
4.3.2.1 Spectral assays
Spectral Assay A
Only the triterpenoid fraction purified from S. frutescens was able to induce a significant Type II
difference spectra at the concentrations tested (Figure 16). The Type II induced difference
spectrum suggests that the triterpenoids bind directly to heme iron.
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Figure 16. Type lJ difference spectrum of microsomal cytochrome P450 enzymes (jcytochrume P4501 = 0.6
11M)induced by the triterpenoid fraction (0.25 mg).
Spectral Assay B
The bioactive compounds were tested for activity using 0.15 mg compound/0.6 ~lM cytochrome
P450. Substrate binding was inhibited by the triterpenoid fraction only, as was shown by the
reduction of the amplitude of the PROG-induced type I difference spectrum in adrenocortical
microsomes. Figure 17 summarizes the inhibition of PROG binding to the microsomal P450
enzymes in the presence of the bioactive compounds. PREG binding was not inhibited by any of
the compounds and the result is therefore not included. However, at a higher concentration, 1.5
mg, the triterpenoid fraction was able to reduce the PREG-induced difference spectrum
illustrated in Figure 18B. Interestingly, the tlavonoids, which are also similar in structure to the
adrenal steroid hormones, did not inhibit binding when 0.15 mg was assayed. Higher
concentrations could, however, not be tested due to a limited supply of the flavonoid fraction.
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Figure 17. Percentage inhibition of PROG (3.2 11M) binding to microsomal cytochrome P450 enzymes
(cytochrome IP4501 = 0.35 11M)by 0.15 mg bioactive test compound. Results are presented as the mean, error
bars represent SEM and n = 3.
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Figure 18. Inhibition of substrate-induced type 1 difference spectra in ovine adrenal mierosomes (cytochrome
IP4501 = 0.35 11M)by 1.5mg triterpenoid fraction. Inhibition of (A) (-), PROG (3.2 11M),(-----) PROG +
triterpenoid and (B) (-), PREG (3.2 11M),(-----) PREG + triterpenoid.
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Figure 19. Percentage inhibition of PROG (3.2 11M)and PREG (3.2 11M)binding to ovine adrenocortical
mierosomes (cytochrome [P450] = 0.35 11M) in the presence of varying concentrations of triterpenoids.
Results are presented as the mean, error bars represent SEM and n = 3.
Figure 18 illustrates the reduction in amplitude of (A) PROG- and (B) PREG-induced difference
spectra by the triterpenoid fraction, Figure 19 illustrates that the triterpenoids exhibit a greater
inhibitory effect on the binding of PROG (P < 0,05) to cytochrome P450 - a 50 % inhibition of
PROG binding is obtained in the presence of 0,6 mg triterpenoids while a 40 % inhibition of
PREG binding necessitates 1,5 mg triterpenoids.
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4.3.2.2. Inhibition of steroid conversion
Conversion Assay A
Since the triterpenoid fraction showed significant inhibition of steroid binding to the cytochrome
P450 enzymes, the conversion of steroids in ovine adrenal mierosomes was assayed in the
presence of this fraction.
Figure 20. Percentage inhibition of PROG (10 JlM) and PREG (10 JlM) conversion in ovine adrenal
mierosomes (cytochrome IP450j = 0.35 JlM) by 0.3 mg triterpenoid. Results are presented as the mean, error
bars represent SEM and n = 2.
Conversion was monitored over a 25 min period and inhibition was observed in the presence of
0.3 mg triterpenoids. PROG conversion was inhibited by 62 % and PREG conversion was
inhibited by 41 % (Figure 20). The metabolites of the conversion assay are not presented, as they
were not sufficiently separated to determine their relative concentrations. Due to a limited supply
of the triterpenoid fraction the experiment could not be repeated to obtain the required
separation.
4.3.3 Inhibition of cytochrome P450enzymes by Sutherlandia tablets
Spectral Assay B
From the previous results it is clear that dried S. frutescens plant material contains compounds
capable of inhibiting the cytochrome P450 enzymes. Since the manufacturing process of
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Sutherlandia in the production of commercially available tablets may influence the activity of
the bioactive compounds, the effect of tablet extracts on steroid binding was investigated and
results are presented in Figure 21.
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Figure 21. Percentage inhibition of DOC (3.2JlM) binding to CYPllBI (cytochrome IP4501= 0.78 JlM), and
PROG (3.2 JlM) and PREG (3.2 11M)binding to microsomal P450 enzymes (cytochrome [P4501= 0.35 11M),by
50 III tablet extracts (0.3 mg/ml). Results are presented as the mean, error bars represent SEM and n = 3.
Only the tablets purchased Health Foods were capable of significantly inhibiting only DOC
binding (P < 0.02). PREG and PROG binding to the adrenal mierosomes were, however, not
significantly inhibited by the concentrations of the tablet extracts tested. Low levels of inhibition
were observed as only 1 % of extracted compounds from a single tablet were added to the
reaction mixture - 3 mg dried plant material was assayed. Since the inhibition of binding of
steroid substrates to cytochrome P450 enzymes by these products is very low no deductions with
regards to the influence of the manufacturing processes on the bioactivity of the Sutherlandia
tablets can be made.
4.4 Discussion
Extracts of S. frutescens and natural compounds previously identified in the plant interact with
CYP Il Bl, CYP 17 and CYP21 as was observed in the assays carried out with the steroidogenic
cytochrome P450 enzymes. Test components influenced enzyme activities by binding to the
cytochrome P450 enzymes, influencing the binding of endogenous substrates and had an effect
on substrate metabolism.
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Aqueous extracts, when assayed in adrenal microsomes, induced a reverse type I difference
spectrum. The binding of reverse type I inhibitors favours a spin equilibrium shift of the ferric
iron to its low-spin form. The sixth axial ligand may therefore be more firmly bound rather than
displaced, as with type I substrates. The exact nature of the interaction is unknown. Since most
reverse type I inhibitors contain oxygen and/or nitrogen, there may be hydrogen bonded
interactions between the inhibitor and the water sixth ligand. If, in the unlikely event, the reverse
type I inhibitor binds to the heme, the interaction is too weak to induce a shift in the absorption
maximum [Lewis, 1996]. It is most probable that these inhibitors bind in the hydrophobic pocket
of the P450 enzyme to a second site different from that occupied by type I substrates.
While only the aqueous extract was able to induce a detectable reverse type 1 spectrum, both
aqueous and methanol extracts were able to inhibit the binding of DOC and PROG to the P450
enzymes in the mitochondria and microsomes, respectively. The inhibition of PREG binding to
the microsomal P450 enzymes was, however not significant (P = 0.25). Although the binding of
PREG to CVP 17 was not inhibited, in vitro investigations revealed that both S. frutescens
extracts were able to inhibit the metabolism of both PROG and PREG by the microsomal P450
enzymes. This suggests that bioactive compound(s) present in the extracts may bind to a site in
the active pocket other than that occupied by PREG and thus not inhibit PREG binding. Since
PROG and DOC binding was inhibited, bioactive compounds in S. frutescens may bind to the
same site or in the same orientation as the natural substrates, or binding may bring about
structural changes of the enzyme which subsequently hampers the binding of the natural
substrates.
Both the hydroxylase and lyase activities of the P450 enzymes are influenced by S. frutescens as
was shown with the inhibition of PROG (~50 %) and PREG (~70 %) metabolism in vitro, by the
aqueous and methanol extracts. When PROG metabolism was assayed the inhibition of CYP21
was greater than the inhibition of CYPI7 by both the aqueous and methanol extracts since the
inhibition of DOC was significantly higher (P < 0.003) than the inhibition of 17-0H-PROG by
the extracts.
Since the mierosomes contain both CYP21 and CVP 17 enzymes, the biological activity of S.
frutescens was investigated in COS 1 cells. The possibility that the extracts could influence the
viability of the cells was considered. Numerous cytotoxic and cell viability assays are currently
Stellenbosch University http://scholar.sun.ac.za
90
available. The choice of the appropriate assay will depend on the cell type, the information
required and the cost involved [Celis, 1998]. Since the assay described in this study set out to
determine whether there was a difference between steroid metabolism in transfected COS 1 cells
in the absence and in the presence of S. frutescens extracts, the measurement of the number of
viable cells or the number of dead cells may be irrelevant. If however, the mechanism of cell
death i.e. apoptosis and/or necrosis was being investigated, the duration of exposure to S.
frutescens extracts and the concentration of compounds in the extracts, become critical [Riss and
Moravec, 2004]. For this study however the determination of the viability of the COS I cells
(cells remaining attached for the duration of the assay) was assayed as described using a relative
inexpensive and readily available protein determination9.
CYP17 from different species was investigated and the influence of S. frutescens extracts on the
catalytic activity of this enzyme differed across species. When the substrate inhibition by the
aqueous and methanol extracts was greater than 80 % the inhibition on the lyase and hydroxylase
activity was similar. Different concentrations of dried S. frutescens plant material are present in
the methanol and aqueous extract, 82 mg/ml and 48 mg/ml, respectively. When comparing
methanol and aqueous extract with similar concentrations of extracted plant material, the
aqueous extract exhibit a greater inhibition of PREG metabolism by baboon CVP 17 than the
methanol extract CP< 0.05). Both the aqueous and methanol extract exhibited a greater inhibition
on the hydroxylase activity of CVP 17 than the lyase activity CP < 0.01). In addition, the
inhibition of the hydroxylase activity of ovine CVP 17 by the aqueous extract was greater than
the inhibition of the lyase activity of the enzyme (P < 0.002). Subtle differences in the inhibition
of the 17- and l ó-hydroxylase activity of human CYPI7 by the methanol and aqueous extract
were observed. Both extracts exhibited a greater inhibition (P < 0.05) on the 16-hydroxylase
activity of human CVP 17. The hydroxylase and lyase activities were influenced in different ways
by the extracts possibly suggesting different mechanisms of action of inhibition of the enzymes.
Furthermore, there were differences in inhibition of the PROG and PREG substrates that suggest
there may be many bioactive compounds present in S. frutescens capable of inhibiting the
catalytic activity of the P450 enzymes. Analysing HPLC fractions of S. frutescens extracts for
inhibitory activity would identify the presence of bioactive compounds in S. frutescens that
interact with the P450 enzymes.
9 http://www.jingmei.com/site/site/zt/Roche/FuGENE%206%20Feature%20Presentation.pdf
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Compounds may influence the binding of the substrate in the active site and possibly also the
binding of other role players involved in the catalytic activity of the enzyme. Compounds may
bind to residues on the surface of the P450 enzyme, which may be important for the binding of
the redox partners. This interaction would still allow the endogenous steroid to bind to the
enzyme but may inhibit substrate conversion by interfering with the interaction of the P450
enzyme with its redox partners and blocking the electron transport chain. In addition, compounds
may inhibit the conversion by interacting with molecular oxygen or the phospholipid
environment, which both playa role in catalytic activity of the P450 enzymes.
The triterpenoid and flavonoid compounds present in S. frutescens, have similar structures to the
steroidogenic enzymes and may thus possess corticomimetic activity. However, only the
triterpenoid fraction was able to bind in the active pocket of the P450 enzyme, inducing a type IT
difference spectrum. Type II inhibitors bind directly to the heme iron, replacing the water
molecule as the sixth axial ligand. The inhibitor-induced type II difference spectrum was,
however, not observed in the presence of the S. frutescens extracts. It can be hypothesized that
the triterpenoids are present at low concentrations and therefore unable to induce a detectable
type II spectrum. Since the triterpenoids are able to induce a type II difference spectrum and the
aqueous extract induced a reverse type] spectrum, the presence of more than one bioactive
compound in S. frutescens with respect to inhibition of the P450 enzymes, is confirmed.
The triterpenoids were able to inhibit the binding of PROG and PREG to the microsomal P450
enzymes as a result of ligating directly to the heme. L-canavanine, GABA, pinitol and the
flavonoids were unable to inhibit the binding of steroids to the P450 enzymes at the
concentrations tested. It is possible that the flavonoids may not be strong inhibitors of P450
enzymes but the lack of inhibition by the flavonoids may be a result of the low concentrations
used in the assays. Due to a limited supply of the flavonoids, higher concentrations could not be
tested. LC-MS analysis identified the presence of aromatic phenolic compounds, with molecular
masses of 740 and 724, in both the methanol and aqueous extract. From the peak intensities it
appears that the aqueous extraction was more successful at extracting these compounds than
methanol extraction. However further HPLC analysis is required to confirm the relative
quantities. An aqueous extract was prepared at 50°C under reduced pressure and the LC-MS
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analysis, interestingly revealed that this extract did not contain the compounds with molecular
masses of 740 and 724. This extract was assayed in ovine adrenal microsornes and exhibited
negligible inhibition on the catalytic activity of the P450 enzymes (results not shown). This
finding suggests that the phenolic compounds with molecular masses of 740 and 724, contribute
to the inhibitory activity observed in the presence of the methanol and aqueous extracts. In some
instances, the aqueous extract prepared at a lower temperature, appeared to stimulate the
catalytic activity of the P450 enzymes present in the microsomal preparation (results not shown).
Natural plant products have been identified to stimulate the activity of liver P450 enzymes. Thus,
it is possible that compounds present in S. frutescens are capable of stimulating the catalytic
activity of the P450 enzymes. Analysis of HPLC fractions of the extracts may be able to identify
the compounds with stimulatory effects.
The inhibition of the metabolism of PROG and PREG by the microsomal P450 enzymes in the
presence of the triterpenoid fraction may be attributed to the fact that they bind directly to the
heme iron. High concentrations of the triterpenoid fraction ~ O.4mM was however required to
achieve an inhibitory effect. PROG binding and conversion was inhibited to a greater degree (P <
0.05) than PREG binding and conversion. It has been suggested that the triterpenoids are present
in relatively low concentrations in S. frutescens plant material [Van Wyk, 2004]. HPLC analysis
of the extracts and triterpenoid fractions would allow the quantification of the concentrations of
triterpenoids present in the plant material and extracts to allow a direct comparison of the results
obtained by the extracts and triterpenoids. One can, however, estimate the concentrations of the
flavonoid and triterpenoid fractions which were assayed using an average molecular mass for
flavonoids and triterpenoids of 730 and 690, respectively. It can therefore be concluded that
triterpenoid concentrations of ~0.4 mM and ~2 mM were used to achieve a 50 % inhibition of
PROG and PREG binding, respectively. These concentrations are exceedingly high compared to
the concentration present in the plant material. This would underlie the hypothesis that it is not
only a single compound interacting with the P450 enzymes, but rather many compounds acting
synergistically.
The commercially available tablets assayed, contain 300 mg dried plant material and the
concentration of dried plant material used in spectral assay B was much similar to the
concentrations of dried plant material in the extracts, 3 mg/ml versus 4.1 mg/ml or 2.4 mg/ml.
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The tablet extracts were prepared at a temperature of 37°C and may therefore contain fewer of
the bioactive compounds. As a result, inhibition of steroid binding to the mitochondrial and
microsomal P450 enzymes was much lower than that observed in the presence of the extracts. In
addition, tablets purchased from different manufacturers showed negligible differences in
inhibition. The active compounds in plants are usually secondary metabolites and their
concentrations vary as a result of season, time of day, soil type and other environmental factors.
The bioactivity of these products may be influenced by the harvesting of different plant
specimens, post-harvesting storage of plant material and by the manufacturing procedures
employed for the development of the tablets. Higher concentrations of tablet extracts would have
to be assayed to allow conclusions to be made about the influence of manufacturing procedures
on the activity of the compounds.
In summary, S. frutescens contains bioactive compounds capable of inhibiting the activity of the
CYPII BI, CYP21 and CYPl7 enzymes involved 111 the biosynthesis of steroids at
concentrations lower than the recommended dosage. A traditional decoction as well as
commercially available tablets of S. frutescens, posses the inhibitory activity and are thus
effective dosage forms for the inhibition of the steroidogenic P450 enzymes and the subsequent
reduction of cortisol biosynthesis. These results provide insight into the mechanism with which
S. frutescens is able to reduce glucocorticoid levels and provides preliminary scientific appraisal
for the stress relieving properties of the plant.
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ABSTRACT
Sutherlandia [rutescens (Cancer bush), a Southern African indigenous plant, is
traditionally used to treat stress related maladies linked to the endocrine system.
Extracts of the shrub were used to investigate the claimed stress-relieving properties
of the shrub. Dysregulation of the stress response is associated with elevated
glucocorticoid levels. A model of chronic intermittent immobilization stress was
investigated in 40 adult male Wi star rats to determine the effect of Sutherlandia.
Immobilization stress resulted in increased corticosterone levels in the control group
while rats receiving Sutherlandia extract showed significantly decreased corticoste-
rone levels (P < 0.005). Since the biosynthesis of glucocorticoids in the adrenals is
catalyzed by the cytochrome P450-dependent enzymes, the influence of Sutherlandia
extracts on adrenal steroidogenesis was determined in ovine adrenocortical micro-
somes and mitochondria, using spectral binding and enzyme conversion assays. Water
extracts showed inhibition of substrate binding to cytochrome P450 2l-hydroxylase
(CYP21) by 38% and cytochrome P450 11~-hydroxylase (CYPllBl) by 60%. The
conversion of progesterone and pregnenolone was inhibited by 34% and 30%,
respectively. Subsequent extractions with chloroform and methanol showed inhibition
of substrate binding and conversion with hydrophobic compounds exhibiting a greater
inhibitory effect on deoxycorticosterone binding to CYP1IBl (30%) and on
progesterone binding to CYP2l (50%). The inhibition of binding of pregnenolone
"Correspondence: A. C. Swart, Department of Biochemistry, University of Stellenbosch,
Stellenbosch 7600, South Africa; E-mail: acswart@sun.ac.za.
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to CYPl7 by the chloroform extract was 62%, with negligible inhibition by the
methanol extract. The chloroform extract showed a greater inhibitory effect than the
methanol extract on progesterone and pregnenolone metabolism (20%-50%).
Key Words: Sutherlandia [rutescens; Steroidogenesis; Cytochrome P450.
INTRODUCTION
Many indigenous plants have long been used as traditional remedies for a variety
of ailments. Sutherlandia jrutescens (Cancer bush) is one such plant and is used to treat
many maladies, including stress related illnesses (1,2). There is, however, little
scientific evidence to support these claims of therapeutic effects. To date few active
compounds have been isolated and characterized from Sutherlandia. Some of these
compounds have been shown to have anticancer, antiinflammatory, and antiviral
properties and are capable of inhibiting nitric oxide synthase (3-6). Sutherlandia has
been anecdotally reported to bring relief to HIV IAIDS and cancer patients, who are
subject to a chronic increase in blood cortisol levels (7,8). Since side effects are not
well established, a toxicity study in vervet monkeys was undertaken. Sutherlandia was
shown to have no toxic or side effects with regards to the parameters measured (9).
Excessive and sustained cortisol secretion resulting from stress and stress related
illnesses has been associated with immunosuppression, cardiovascular disease, and a
host of other ailments (7, I0). Since adrenal cytochromes P450 are responsible for the
biosynthesis of glucocorticoids, cortisol and corticosterone, a possible target tissue for
testing the antistress function of Sutherlandia, is the adrenal gland. The therapeutic
properties of Sutherlandia were therefore investigated in Wistar rats and the influence
on adrenal steroidogenesis was determined.
The effect of Sutherlandia on plasma corticosterone and testosterone levels in adult
male Wistar rats, subjected to immobilization stress, was determined by administering
extracts intraperitoneally. The influence of Sutherlandia on the cytochrome P450
enzymes, which catalyze the biosynthesis of cortisol precursors in the adrenal, was
subsequently investigated-the inhibition of substrate binding to these enzymes
and steroid metabolism in ovine adrenal microsomes, in the presence of Sutherlandia,
was determined.
MATERIALS AND METHODS
In Vivo Studies
The effect of Sutherlandia was determined in adult male Wistar rats subjected to
stress as previously described (I l. Forty rats were divided into 4 mass-matched groups
(n = 10). Two groups were immobilized for 2 h once a day for 28 days in addition to
receiving either Sutherlandia extract (IS) or placebo (isotonic saline) (lP) and two
control groups received either Sutherlandia extract (CS) or placebo (CP). An aqueous
extract was administered intraperitoneally, 2 mg/0.5 ml twice daily for 28 days.
Serum corticosterone and testosterone concentrations were determined by radio
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immunoassays (Biotrak RPA 548, Amersham) and immunoassays (Advia Centaur,
Bayer Diagnostics), respectively.
Preparation of Sutherlandia Extracts
A aqueous extract was prepared by boiling 2.16 g dried Sutherlandia [rutescens in
275 ml deionized water for 30 min. The extract was lyophilized, redissolved in 13 ml
deionized water and subsequently centrifuged at 6000 g for 5 min.
Dried plant material, 18.6 g, was extracted with 250 ml chloroform and methanol
for 5 and 8 h, dried and redissolved in 35 ml polyethylene glycol (PEG) 400 (BDH
chemicals Ltd. UK) and deionized water, respectively (II).
Cytochrome P450 Binding and Substrate Conversion Assays
Ovine adrenal mierosomes and mitochondria were prepared as previously described
(12). The cytochrome P450 content was determined by the carbon monoxide method
using an extinction coefficient (E) of 91 em-I. mM-I(13).
Spectral assays were carried out and the induced difference spectra recorded
between 360 nm and 500 nm (11). Steroid substrates (Sigma Chemical Co. St. Louis,
MO, USA) dissolved in ethanol (1.6 mM), were added to the mierosomes (0.33 u.M
P450) and mitochondria (0.78 ~IM P450) to a final concentration of 3.2 ~IM. Inhibition
of pregnenolone (Preg), progesterone (Prog), and deoxycorticosterone (DOC) binding
was measured by a decrease in the induced difference spectrum upon the addition of
50 ~t1 Sutherlandia extracts (9).
Adrenal mierosomes (0.35 ~IM P450) were preincubated at 37°C and Prog, I0 ~IM,
and Preg, 10 u.M, metabolism assayed in the presence of 50 ~ll extract, tritiated steroid
(PerkinElmer Life Sciences Boston, MA), 0.4 U isocitrate and I mM NADPH (Roche,
Germany) in a final reaction volume of I ml (14). Aliquots, 50 ul, were extracted with
dichloromethane and Prog and Preg metabolites were separated on a Novapak'" CI8
and C8 column, respectively, at a flow rate of I ml/min with a Waters (Milford, MA)
HPLC coupled to a Waters 700 satellite WISP™ automatic injector and a Flo-One
liquid scintillation spectrophotometer (Radiomatie, Tampa, FL) (15).
RESULTS
In Vivo Studies
Plasma analysis showed that immobilization stress produced significantly increased
corticosterone levels (P < 0.05) and decreased testosterone levels (P < 0.05). These
findings are reflected in the significantly higher corticosterone:testosterone ratio seen in
the stressed versus the control groups receiving the placebo (P < 0.05). In the two
groups subjected to stress, the group receiving the Sutherlandia supplement showed
significantly decreased corticosterone plasma levels (P < 0.005). Interestingly, corticos-
terone levels were significantly higher in the control group receiving the Sutherlandia
supplement than in the control group receiving the placebo (P < 0.05). Both these
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Table 1. Inhibition by methanol and chloroform extracts of steroid binding (0.78 >tM P450) and
substrate conversion (0.3 >tM P450) in ovine adrenal mitochondria and microsomes.
% Inhibition of
steroid (3.2 ulvl) binding
% Inhibition of
steroid (10 ,1M)
conversion
DOC Prog Preg Prog Preg
Methanol extract
Chloroform extract
59
80
17
67
NS*
62
52
100
72
93
*Not significant.
control groups, CP and CS, had significantly higher testosterone levels than the stressed
group receiving the Sutherlandia supplement (P < 0.01 and P < 0.05).
Cytochrome P450 Binding and Conversion Assays
The binding of DOC to CYP 11B 1 exhibits a type 1 induced spectrum (Fig.1A).
Varying degrees of inhibition on substrate binding was observed in the presence of
Sutherlandia extracts, indicated by the reduced amplitude in the difference spectra. The
aqueous extract inhibited the binding of DOC by 60%. While the metabolism of both
Prog and Preg was inhibited, the inhibition of Preg binding was negligible (Fig. IB).
Typical HPLC analyses of steroid metabolites present in the medium after 10 min are
shown in Fig. 2.
A
0.03
500
B
60
50
c: 40,g
:0 30:i:c:
;!. 20
10
0
Prog
==Binding
I2Z!ZJ Conversion0.02
--DOC
--.DOC+ extract
0.01
-0.03
Wavelength (nm)
-0.01
-0.02
Preg
Figure 1. (A) The influence of the water extract on DOC-induced difference spectra. Inhibition*,
60%, was assayed in ovine adrenal mitochondria (0.78 >tM P450), steroid (3.2 >tM DOC) and
Sutherlandia water extract (50 ul), (B) The influence of the water extract on Prog and Preg binding
and metabolism. Inhibition was assayed in ovine adrenal mierosomes (0.78 >tM P450 in binding
studies and 0.33 >tMP450 in conversion assays), Sutherlandia water extract (50 ul), steroid (3.2 >tM
for binding assays and 10 >tM for steroid metabolism assays). *8.A/(390-420)/8.AC(390-420l x 100.
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Figure 2. HPLC analysis of pregnenolone (10 uM) (A and B) and progesterone (10 pM) (C and
D) metabolites in ovine adrenal mierosomes at 10min. Products formed without Sutherlandia are
illustrated in A and C. Peaks on chromatogram A and B are: I, Preg (7.5 min); 2, 17-0H Preg
(3.5 min); 3, DHEA (2.2 min). Less product was observed in the presence of 50 ul of the water
extract. Peaks on chromatogram for e and D are: I, Prog (23 min); 2, 17-0H Prog (19.5 min); 3,
DOe (16.8 min); and 4, deoxycortisol (10 min).
Steroid binding and conversion was inhibited in the presence of both methanol
and chloroform extracts (Table I). Chloroform extracts displayed greater inhibition of
steroid binding and substrate conversion than the methanol extracts, while the latter did
not inhibit Preg binding as was previously seen with the aqueous extracts.
DISCUSSION
The effects of Sutherlandia treatment on chronic intermittent immobilization stress
manifested as a significant decrease the corticosterone response, supporting the
indigenous knowledge of Sutherlandia's stress relieving properties. Inadvertently this
result may also support the claims that Sutherlandia can improve the quality of life of
cancer and HIV/AIDS patients.
The inhibitory effects of Sutherlandia extracts on the cytochromes P450, which
catalyze the biosynthesis of cortisol and its precursors, substantiated the above findings.
The aqueous extract inhibited substrate binding to the microsomal (CYP 17) and
mitochondrial (CYPIIBI) cytochrome P450 enzymes. Since compounds in the plant
material inhibit enzyme/substrate binding, steroid production would ultimately be
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affected. However, both CYP17 and CYP21 were inhibited by chloroform and
methanol extracts with the hydrophobic compounds showing a far greater inhibitory
effect on the biosynthesis of steroid intermediates than the hydrophilic compounds
present in both the methanol and aqueous extracts.
Interestingly, basal corticosterone concentrations were significantly elevated in
control rats receiving Sutherlandia supplements when compared to placebo rats in the
absence of an additional stressor. Sutherlandia may act as an adaptogen effecting a
more functional basal serum corticosterone level. Aqueous extracts prepared under
milder conditions, was found to stimulate the conversion of Preg by CYP 17 in COS I
cells and in adrenal mierosomes (unpublished results).
Our data shows that hydrophilic compounds in the plant extract did not inhibit
substrate binding to CYPI7 but did, however, inhibit the metabolism of Preg indicating
that within the microsomal environment, compounds in Sutherlandia may possibly
affect other role players in the catalytic reaction. It is clear that Sutherlandia contains
compounds that affect adrenal steroidogenesis, but these active compounds are possibly
complexed in the plant material requiring specific extraction conditions for the
dissociation and subsequent activation of compounds.
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Chapter Six
Conclusion
S. frutescens is one of 3000 medicinal plants in South Africa and is considered the most
profound adaptogenic tonic. Claims that S. frutescens can be used in the treatment of the
symptoms associated with HIV/AIDS and cancer have prompted scientific investigations into the
validation of the anecdotal therapeutic claims of the plant. In addition, S. frutescens is reported to
improve the quality of life in general and has been used traditionally to treat a multitude of
maladies including colds, flu, stomach problems, inflammation and stress [Van Wyk and Wink,
2004].
Psychological and physical stress activates the HPA-axis stimulating the increased production of
the glucocorticoids, cortisol and corticosterone. The HPA-axis is intricately regulated by
neuroendocrine signals with the glucocorticoids regulating the activity of the HPA-axis by
negative feedback. In chronic stress situations, which include psychological stress, HIV/AIDS
and cancer, the negative feedback regulation is interrupted resulting in permanently elevated
plasma glucocorticoid levels. Prolonged exposure to cortisol has been associated with many
adverse effects [Chrousos and Gold, 1998]. The deleterious effects of elevated levels of cortisol
may be alleviated by inhibiting the enzymes responsible for the biosynthesis of cortisol. S.
frutescens may relieve the symptoms of stress and improve the quality of life of cancer and
HIV/AIDS patients by inhibiting the catalytic activity of steroidogenic cytochrome P450
enzymes, therefore decreasing circulating glucocorticoid concentrations.
Plasma cholesterol is the steroid substrate for the biosynthesis of cortisol. The adrenal
cytochrome P450 enzymes are heme proteins which catalyse the complex reactions involved in
steroid hormone biosynthesis. The reactions catalyzed by the enzymes require the transfer of two
electrons from NAD(P)H either via cytochrome P450 reductase in the endoplasmic reticulum, or
via ferredoxin reductase in the mitochondria. The mitochondrial P450 enzymes, CVP Il A,
CYP1IB1 and CYPIIB2, employ an iron sulphur protein, adrenodoxin, and adrenodoxin
reductase to transport electrons. The adrenodoxin protein shuttles the electrons from the
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reductase to the P450 enzyme. The microsomal P450 enzymes, CYP 17 and CYP21, acquire their
electrons directly from the reduced reductase. Due to the complex nature of these enzymes, there
are many ways to inhibit the catalytic activity of the enzyme. Inhibitory compounds can bind to
the active site and induce a conformational change, which prevents binding of the natural steroid
substrates. Compounds may also bind to other sites on the enzyme and may thus inhibit the
binding of electron transport proteins. The phospholipid environment and the availability of
molecular oxygen are other factors that playa role in the catalytic activity of the P450 enzymes,
thus inhibitory compounds may interfere with these parameters.
UV!Visible spectrometry revealed that components of S. frutescens were able to bind to the P450
enzymes and inhibit the type I difference spectrum induced by the binding of natural steroid
substrates. The uncommon reverse type I spectrum was induced by the aqueous extract of S.
frutescens, suggesting that components of S. frutescens bind in the heme pocket of the enzyme to
a site different from that occupied by the natural steroid substrates. Compounds that access and
bind to the active site, are usually similar in structure to the natural steroid substrates of the
enzyme. The flavonoids and triterpenoids present in many plants have a similar structure to these
natural steroids. The triterpenoids present in S. frutescens were able to elicit a type Il spectrum,
showing thus that these compounds bind directly to the heme in the active pocket of the enzyme,
displacing the sixth axial ligand of the heme. The flavonoid compounds present in S. frutescens
were unable to induce a difference spectrum or inhibit the binding of natural steroids to the P450
enzymes. It is possible that the flavonoids may not be strong inhibitors of P450 enzymes, but the
lack of inhibition by the flavonoids may be a result of the low concentrations used in the assay.
The induction of a type II and reverse type I difference spectrum establishes the presence of
more than one compound in S. frutescens with the potential to interact with the P450 enzymes.
In vitro and in vivo assays demonstrated that S. frutescens extracts were able to inhibit the
catalytic activity of the P450 enzymes present in the endoplasmic reticulum of the adrenal
cortex. Although the inhibition of PREG binding to the microsomal enzymes by the methanol
and aqueous extracts was negligible, both extracts were capable of inhibiting the metabolism of
PREG suggesting that components of the extracts possibly interfere with other role players
involved in cytochrome P450 catalysis such as the phospholipid environment or the redox
partners employed by the enzymes. Both the methanol and aqueous extract inhi bited both CYP21
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and CYP17 in COS 1 cells. The inhibition of CYP21 was greater than inhibition of CYP17.
Furthermore, the degree of inhibition of CYP17 differed across species but both extracts
inhibited the hydroxylase activity ofCYP17 more potently than the lyase activity of the enzyme.
UV analysis of the methanol and aqueous extracts identified two prominent peaks which
absorbed at the wavelength of aromatic compounds and may thus be phenolic compounds
present in S. frutescens such as the flavonoids. These peaks have molecular weights of 740 and
724, which were determined by negative ion electrospray mass spectral analysis. An aqueous
extract of S. frutescens prepared at a lower temperature under reduced pressure did not contain
these prominent peaks. In addition, the inhibition of the catalytic activity of the microsomal P450
enzymes in the presence of this aqueous extract was negligible. This result suggests that the
compounds with molecular weights of 740 and 724 may contribute considerably to the inhibitory
effect of S. frutescens on the steroidogenic P450 enzymes. Furthermore, the aqueous extract
prepared at a lower temperature often stimulated the catalytic activity of the P450 enzymes.
Future investigations would involve collecting HPLC fractions of the extracts to determine
which compounds are responsible for influencing the catalytic properties ofP450 enzymes.
In an investigation in rats, it was shown that rats treated with S. frutescens not only exhibited
decreased plasma glucocorticoid levels in response to chronic immobilization stress but also
increased basal corticosterone levels in non-stressed rats. S. frutescens may therefore exert its
stress relieving properties by influencing the HPA-axis acting as an adaptogen Ca substance
which increases the body's ability to adapt and increase resistance to stress, normalising body
functions through allostasis [Smith and Myburgh, 2004]) as well as by down-regulating
glucocorticoid production. The inhibition of elevated glucocorticoid levels in response to
chronic stress may be attributed to the inhibitory effect of S. frutescens on the steroidogenic P450
enzymes. Future investigations would involve examining the anti-stress properties on other
potential target tissues such as the hippocampus, hypothalamus and pituitary.
In summary, these results provide preliminary scientific appraisal of the stress relieving
properties of the plant by providing insight into the mechanism with which S. frutescens is able
to reduce glucocorticoid levels. Commercially available tablets also contain the inhibitory
activity and are thus an effective dosage form for the inhibition of the P450 enzymes. Although
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safety and toxicity reports have suggested that S. frutescens plant material is not toxic at nine
times the recommended dose, other factors need to be considered before the plant is prescribed
for medicinal purposes. It has been reported that S. .frutescens is able to inhibit the drug
metabolizing cytochrome P450 enzymes and thus may influence, delay, compromise or replace
the efficacy of conventional medicines when these are used in conjunction with S. frutescens.
This characteristic of S. frutescens highlights the importance of scientific investigations on the
medicinal properties of traditional medicine in general. To bring traditional medicine to the level
of efficacy and safety where it can be regarded as an acceptable alternative to western healthcare
systems requires scientific validation, strict regulation and trained healthcare practitioners.
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